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Tausta: Antibiootit ovat olleet tärkeä tekijä bakteeriperäisten infektiotautien kuolleisuuden romahduksessa 1900-luvulla. 
Bakteerit ovat kuitenkin erittäin tehokkaita mukautumaan ympäristönsä muutoksiin lyhyen elinkaarensa vuoksi. Näin 
ollen bakteerien antibioottiresistenssin kehitys on luonnollisesti seurannut valtavaa maailmanlaajuista antibioottien 
käyttöä. Nykyinen tilanne on, että bakteerien antibioottiresistenssi kehittyy nopeammin kuin uusia antibiootteja löydetään 
ja kehitetään. Gram-negatiivisten bakteerien kolme pääasiallista resistenssistrategiaa ovat: antibiootin kohderakenteen 
muokkaus, antibiootin entsymaattinen inaktivaatio ja solun sisäisen antibioottikonsentraation laskeminen ulkokalvon 
toimintaa muokkaamalla. Bakteerit laskevat solun sisäistä antibioottikonsentraatiota muun muassa efluksipumpuilla, 
joista merkittävimpiä antibioottiresistenssin kannalta ovat RND-perheen effluksipumput. RND-efluksipumput toimivat 
tyypillisesti osana kolmiosaista rakennetta, joka mahdollistaa antibioottien pumppaamisen solun ulkoiseen tilaan. RND-
pumppuja vastaan on kehitetty useita inhibiittoreita, mutta yksikään ei ole saavuttanut lääkekehityksen kliinistä vaihetta.  
            
Tavoitteet: 384-kuoppalevyformaatissa toimivan seulontamenetelmän kehittäminen E. colin (BAA1161) 
efluksipumppuinhibiittorien seulomiseen, sekä kehitetyn menetelmän testaaminen.   
 
Menetelmät: Absorbanssimittauksen riittävän herkkyyden varmistaminen bakteerikannan (BAA1161) kasvun 
seurantaan 384-kuoppalevyformaatissa. Seulontamenetelmässä käytettävän antibiootin (piperasilliini) ja positiivisena 
kontrollina käytettävän efluksipumppuinhibiittorin (meflokiini) BAA1161 kasvua estävän konsentraation (MIC) 
määrittäminen sekä 96- että 384-kuoppalevyformaatissa. Piperasilliinin ja meflokiinin BAA1161:n kasvua estävän 
synergian varmistaminen 96- ja 384-kuoppalevyformaateissa checkerboard-menetelmällä. Sijainnin vaikutuksen 
selvittäminen 384-kuoppalevyllä. Korkeimman BAA1161:n kasvuun vaikuttamattoman DMSO-konsentraation 
määrittäminen 384-kuoppalevyformaatissa. 126 luontoperäisen yhdisteen seulominen 384-kuoppalevyillä kehitetyn 
menetelmän testaamiseksi. Seulonta suoritettiin neljällä rinnakkaisella näytteellä perustuen seulottavien yhdisteiden 
bakteerin kasvua estävään vaikutukseen piperasilliinin kanssa. Yhdisteille, jotka osoittivat seulonnassa BAA1161:n 
kasvua estävää vaikutusta, suoritettiin annos-vaste -kokeet sekä piperasilliinin kanssa että ilman 384-kuoppalevyllä.       
 
Tulokset ja pohdinta: Absorbanssimittaus osoittautui riittävän herkäksi menetelmäksi BAA1161:n kasvun mittaamiseen 
384-kuoppalevyllä. 96- ja 384-kuoppalevyillä meflokiinin MIC-arvoksi saatiin 32 μg/ml. Piperasilliinin MIC-arvoksi saatiin 
1024 μg/ml 96-kuoppalevyllä, mutta 384-kuoppalevyllä MIC-arvossa oli vaihtelua. Piperasilliini ja meflokiini osoittivat 
synergistista BAA1161:n kasvun estoa checkerboard-kokeissa. Kuopan sijainnin mahdollista vaikutusta menetelmän 
tuloksiin ei voitu arvioida, koska piperasilliinin vaikutuksessa BAA1161:n kasvuun oli suurta sattumanvaraista vaihtelua. 
Tämä sattumanvaraisesti toistuva ilmiö, jossa piperasilliini esti osassa kuoppia kokonaan tai lähes kokonaan BAA1161:n 
kasvun pitoisuudella joka oli alle MIC:n, toistui myös kaikissa seuraavissa kokeissa 384-kuoppalevyllä. Yksi mahdollinen 
syy tähän 384-kuoppalevyformaatissa toistuvaan ilmiöön on BAA1161 kannan heterogeenisyys piperasilliiniresistenssin 
suhteen. Testiseulonnassa neljä yhdistettä, jotka kaikki sisälsivät gallushappoesterin, osoittivat lupaavaa aktiivisuutta. 
Nämä yhdisteet olivat: epigallokatekiinigallaatti, hamamelitanniini, isopropyyligallaatti ja oktyyligallaatti. 
Hamamelitanniinin ja oktyyligallaatin teho osoittautui synergistiseksi piperasilliinin kanssa annos-vaste-kokeessa.  
 
Johtopäätökset: Kehitettyä menetelmää voidaan hyödyntää uusien efluksipumppuinhibiittorien seulontaan. 
Menetelmän jatkokehittäminen lienee kuitenkin järkevää piperasilliinin vaikutuksen vaihtelun poistamiseksi ja siten 
menetelmän luotettavuuden lisäämiseksi. Menetelmän kuoppalevyformaattia vaihdettaessa tulisi myös kiinnittää 
erityistä huomiota tekijöihin jotka saattavat vaikuttaa menetelmän toimivuuteen uudessa formaatissa. Testiseulonnan 
perusteella gallushappoesterit ovat kiinnostava yhdisteryhmä, joiden antibioottien tehoa lisäävää vaikutusta 
kannattanee tutkia lisää tulevaisuudessa.  
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Background: Antibiotics have been an important factor in the dramatic decrease of infectious disease mortality in the 
20th century. Bacteria are, however, very quick to respond to the changes in their environment because of their short 
life cycle. Thus, the development of bacterial antibiotic resistance is a natural consequence of the enormous worldwide 
antibiotic use. The current situation is that the antibiotic resistance develops faster than novel antibiotics are found and 
developed. The three main resistance strategies of Gram-negative bacteria are: modification of the antibiotic target, 
enzymatic inactivation of the antibiotic and reduce of the intracellular antibiotic concentration by changing the function 
of the outer membrane. To decrease the intracellular antibiotic concentration bacteria use efflux pumps. RND efflux 
pumps are the most important family of efflux pumps regarding antibiotic resistance. They typically function as a part of 
a tripartite structure which allows the efflux of antibiotics to the extracellular space. Multiple inhibitors have been 
developed against RND efflux pumps but none has reached the clinical stage of drug development. 
            
Objectives: Development and testing of a 384-well plate method for screening efflux pump inhibitors for E. coli 
(BAA1161) efflux pumps.  
 
Methods: Verifying that the absorbance measurement is a sensitive enough method for measuring the bacterial 
(BAA1161) growth in 384-well plate format. The antibiotic chosen to be used in the screening method was piperacillin 
and the positive control efflux pump inhibitor was mefloquine. Determining the minimum growth inhibiting concentrations 
(MICs) of piperacillin and mefloquine in 96- and 384-well plate formats. Verification of the synergistic growth inhibitory 
effect of piperacillin and mefloquine with the checkerboard method in 96- and 384-well plate formats. Determining the 
positional effect in the 384-well plate. Determining the highest DMSO concentration without effect on the growth of 
BAA1161. Screening of 126 natural compounds in 384-well plates to test the developed method. Screening was done 
in quadruplicates based on the growth inhibitory effect of the natural compounds when combined with piperacillin. Dose-
response assay was conducted in combination with and without piperacillin with the compounds that showed growth 
inhibiting effect during screening.           
 
Results and discussion: Absorbance measurement was sensitive enough method for measuring the BAA1161 growth 
in the 384-well plate. MIC value of mefloquine was 32 μg/ml in both plate formats. Piperacillin’s MIC was 1024 μg/ml in 
the 96-well plate, but on the 384-well plate there was variation in the MIC. Piperacillin and mefloquine showed synergistic 
effect on BAA1161 growth inhibition in the checkerboard assays. Positional effect could not be determined, because of 
the variation in the BAA1161 growth inhibition effect of piperacillin. This randomly occurring phenomenon were 
piperacillin inhibited BAA1161 growth completely or almost completely with sub-MIC concentration was encountered in 
all the subsequent experiments in the 384-well plate format. One possible reason for this phenomenon, occuring in the 
384-well plate format, could be piperacillin heteroresistance of BAA1161 strain. In the test screen, four compounds, 
which all included gallic acid ester, showed promising activity. These compounds were: epigallocatechin gallate, 
hamamelitannin, isopropyl gallate and octyl gallate. In the dose-response assay, hamamelitannin’s and octyl gallate’s 
effect was synergistic with piperacillin.  
 
Conclusions: The developed method can be used to screen novel efflux pump inhibitors. However, to increase the 
reliability of the method, further optimization is required to eliminate the variability in the effect of piperacillin. When plate 
format of a method is changed, factors which could affect the functionality of the method in the new format should be 
carefully assessed. Based on the test screed, gallic acid esters are interesting compounds which combined effects with 
antibiotics should be studied in the future experiments. 
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1. INTRODUCTION 
 
The era of modern antibiotics started in 1930s with sulfamidochrysoidine (Dodds 2017). 
And since then the role of infectious diseases as a cause of death has dropped 
dramatically. For instance in US in 1937 mortality of infectious diseases was 283 out of 
100 000 persons which dropped to 59 by 1996 (Armstrong et al 1999). Antibiotics have 
played a prominent role in this development but it has to be remembered that also other 
factors like vaccination, sanitation and improved living conditions have supported this 
development. Antibiotics have had especially large impact on the decrease of childhood 
mortality (Piddock 2012). 
  
However, along with the development of antibiotics a new problem evolved, bacterial 
antibiotic resistance. Antibiotic resistance is a natural consequence of increased use of 
antibiotics. Bacteria are very quick to respond to the changes in their environment and to 
evolve because of their short life cycle (Piddock et al 2012). Unfortunately, antibiotics in 
their environment are not an exception. Evolution of antibiotic resistance was also not a 
surprise as Alexander Fleming already warned about it in his Nobel lecture in 1945 
(Fleming, 1945). 
 
Antibiotic use by humans is not the only reason for the development of antibiotic 
resistance. Antibiotics are also used in massive amounts for animals, even for non-
therapeutic purposes, such as increasing feeding efficacy of food producing animals 
(Dodds 2017). In fact, in US most of the antibiotics by mass were consumed by food-
producing animals in 2011. This extensive use of antibiotics in animals is connected to 
the global problem of antibiotic resistance and for some bacterial species food-producing 
animals have even become reservoirs of resistant strains. 
 
The present situation is that resistant strains of pathogenic bacteria are occurring with 
increasing frequency and antibiotics against which resistance has not evolved are 
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discovered with decreasing frequency (Dodds 2017). The big pharmaceutical companies 
have lost a lot of their interest in the development of novel antibiotics and the economic 
reasons for that are clear (Piddock 2012). Antibiotics are usually used only for short 
periods of time and use of new antibiotics is usually restricted if resistance has not evolved 
against them. Thus, the ability to respond to antibiotic resistance has not substantially 
improved since the carbapenems in 1985 (Theuretzbacher, 2017). To globally assess the 
magnitude of antibiotic resistance World Health Organization (WHO) composed the 
report called: Antimicrobial Resistance Global Report (2014) (WHO, 2014). In the report 
WHO concluded that antimicrobial resistance has reached alarming levels and there are 
serious shortcomings in its surveillance. For instance, Escherichia. coli, which is the most 
frequent cause of urinary tract and blood stream infections, was found to have at least 
48% resistance level to third generation cephalosporins and fluoroquinolones in at least 
one country of each WHO region (WHO, 2014). The qualitative and quantitative 
differences in the antibiotic resistance are large between countries and regions. All thing 
considered the return of an era when common infections and small injuries possessed 
substantial risk of death is not impossible.     
 
The objective of the following literature review is to give an overview of the different 
mechanisms which Gram-negative bacteria (GNB) have developed to resist antibiotics. 
A second objective is to give more detail information of the function of resistance 
nodulation division (RND) efflux pumps and molecules which have been developed to 
inhibit their function. First four antibiotic resistance strategies of GNB will be presented. 
Then structure and function of AcrB, the main efflux transporter of E. coli, is reviewed. 
And finally, molecules which have been developed to inhibit AcrB and antibiotic 
resistance it causes are presented. The objective of the experimental part was to develop 
and miniaturize a screening assay for finding new molecules that could inhibit the 
antibiotic resistance mediated by efflux pumps of E. coli. 
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2. LITERATURE REVIEW 
 
2.1 Antibiotic resistance mechanisms of Gram-negative bacteria 
 
Antibiotic resistance mechanisms of GNB can be divided in at least three main strategies. 
These are: modification of the antibiotic target which results in hindered antibiotic 
binding, enzymatic inactivation of the antibiotic and decreased intracellular antibiotic 
concentration by altered outer membrane function. These resistance mechanisms differ 
for instance in specificity, efficacy, dissemination and origin. Bacteria often use multiple 
of these mechanisms concurrently and sometimes it is even required for clinically relevant 
resistance (Piddock 2006; Rodriguez-Martinez et al. 2016). Multiple resistance 
mechanisms utilize specific bacterium expressed proteins like efflux pumps and enzymes. 
Genes of these proteins can be chromosomally or plasmid encoded (Cag et al. 2016; Li et 
al. 2015). Plasmids allow horizontal gene transfer between different bacterial strains and 
species resulting in dissemination of the resistance mechanism. The level of antibiotic 
resistance and bacterial susceptibility to antibiotics is often measured with minimal 
inhibitory concentration (MIC). Clinical and Laboratory Standards Institute (CLSI) 
defines the MIC as “the lowest concentration of an antimicrobial agent that prevents 
visible growth of a microorganism in an agar or broth dilution susceptibility test” (CLSI, 
2012). 
 
2.1.1Antibiotic target structure modification  
 
Modification of the antibiotic target structure is a common strategy for pathogenic 
bacteria to prevent the effect of antibiotic and to induce resistance against it. However, as 
the antibiotic targets have been selected based on their vital role for either survival or 
growth of the bacteria the modification has to be such that it prevents antibiotic binding 
without inactivating the target. The modification of the antibiotic target can occur by 
different mechanisms. Resistance causing target modification mechanisms include 
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mutations in the gene of the target protein, enzymatic modification of the target structure 
and expression of target structure binding proteins that inhibit antibiotic binding. 
 
Mutations in the quinolone target enzymes gyrase and topoisomerase IV are the most 
common mechanism for fluoroquinolone resistance (Aldred et al. 2014). Location, type 
and quantity of gyrase and topoisomerase IV mutations affect the resulting resistance 
level. (Hopkins et al. 2005). Similar mutations can also result in different level of 
resistance depending on the bacterial species.  Usually mutation in one target enzyme 
gene results in only low level of resistance to fluoroquinolones while selection for high 
level of resistance normally results in mutations in the genes of both quinolone target 
enzymes (Price et al. 2003; Aldred et al. 2014).  Mutations in clinically found 
fluoroquinolone resistant strains are usually located in specific areas of the gyrase and 
topoisomerase IV genes, called quinolone resistant determining regions (Hopkins et al. 
2005).  
 
Modification of antibiotic target structure can also be enzymatic. In fact, posttranslational 
enzymatic antibiotic target modification is a common mechanism for resistance to 
bacterial ribosome targeting antibiotics like aminoglycosides, macrolides, lincosamides 
and streptogramin Bs (Wright 2011). For instance, aminoglycoside and macrolide 
resistance is mediated by 16s and 23s rRNA methyltransferases. Site-specific rRNA 
methylation by 16s methyltransferases inhibits aminoglycoside binding to 30S ribosomal 
subunit and prevents the following obstruction of protein synthesis (Doi et al. 2016). Also 
the binding of macrolides to 50S subunit of bacterial ribosome can be blocked by 
enzymatic methylation of rRNA (Gomes et al. 2016). Macrolide resistance is caused by 
methyl transferases that target the 23s rRNA of the 50S ribosomal subunit. Both of these 
rRNA targeting methyltransferases disseminate between pathogenic bacteria by plasmids 
(Doi et al. 2016; Gomes et al. 2016). Both 16s and 23s rRNA methyltransferases are also 
found and probably originate from antibiotic producing bacteria (Roberts 2004; Doi et al. 
2016). 
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The third mechanism of antibiotic target modification is the target protection by 
bacterium expressed proteins. Qnr-proteins are around 200 amino acids long 
fluoroquinolone resistance mediating proteins that spread between pathogenic bacteria in 
plasmids (Aldred et al. 2014; Rodriguez-Martinez et al. 2016). Qnr-proteins belong to the 
pentapeptide repeat protein family and contain tandemly repeating amino acid domains 
(Rodriguez-Martinez et al. 2016). Plasmids that carry qnr-genes typically carry other 
additional resistance genes, also against other antibiotics. Qnr-proteins inhibit 
fluoroquinolone effect by binding to the target enzymes gyrase and topoisomerase IV and 
by decreasing the binding of these target enzymes to DNA (Aldred et al. 2014; Rodriguez-
Martinez et al. 2016). Qnr-proteins typically cause only a low level of resistance to 
quinolones (Rodriguez-Martinez et al. 2016). However, qnr-genes promote emergence of 
resistance mutations and may cause high level of resistance when combined with other 
mechanisms of resistance. Qnr-proteins protect bacteria also from other compounds with 
similar mechanism of action to quinolones. The origin of qnr-genes is in the days before 
medical use of quinolones, supposedly in the water microbes of the environment. 
 
2.1.2 Enzymatic inactivation of antibiotics 
 
The second of the three main bacterial antibiotic resistance strategies is enzymatic 
inactivation of antibiotics. Multiple classes of antibiotic inactivating enzymes are 
expressed by pathogenic GNB. Some of these enzyme genes are chromosomal and some 
carried in plasmids (Cag et al. 2016). Seems likely that at least some of the resistance 
enzymes have evolved before the medical use of antibiotics. It is proposed that some β-
lactamases have evolved even before the divergence of bacteria to Gram-positive and 
Gram-negative species (Hall and Barlow, 2003). Also findings of Bhullar et al. (2012) 
support the claim that the origin of antibiotic inactivating enzymes dates to the time before 
medical use of antibiotics. Bhullar et al. found bacteria capable of enzymatically 
inactivate β-lactams, macrolides and chloramphenicol from a cave that has been 
practically isolated from the outer world for over 4 million years. Bacterial strains from 
the cave were also less resistant to synthetic antibiotics ciprofloxacin and linezolid 
compared to natural product antibiotics.  
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The majority of enzymes that mediate antibiotic resistance catalyse either hydrolysis of 
the antibiotic or group transfer to the antibiotic (Wright 2005). Enzymes mediating 
hydrolysis of antibiotics include both amidases and esterases. Enzymes responsible for 
group transfer include acyltransferases, phosphotransferases, thioltransferases, 
nucleotidyltransferases and glycosyltransferases. Because amidases and esterases unlike 
the transferases require only water as a co-substrate they can be excreted to extracellular 
space, thus allowing inactivation of the antibiotic even before reaching the bacterium. To 
prevent the enzymatic inactivation of antibiotics, antibiotic structures have been modified 
and enzyme inhibitors have been developed. 
 
β-lactamases are encoded by the bla-genes. They are the most common reason for β-
lactam resistance in clinically relevant GNB (Bush and Jacoby 2010). β-lactamases are 
amidases that inactivate the β-lactams by hydrolysis of the β-lactam ring (Wright 2005). 
β-lactamases can be divided into two groups based on the hydrolysis mechanism. 
Metallo-β-lactamases catalyse the hydrolysis by activating the water molecule with a 
Zn2+-ion. Serine-β-lactamases hydrolyse the β-lactams in a two-step reaction. First the 
active site serine causes the ring opening by nucleophilic attack, which is followed by 
hydrolysis of the covalent enzyme-antibiotic intermediate. Hydrolysis mechanisms of the 
two β-lactamase groups are shown in the figure 1. β-lactamases can also be classified to 
four groups (A-D) based on the protein structure and to three groups with multiple 
subgroups based on their functionality (Bush and Jacoby 2010). Other bacterial enzymes 
that hydrolyse antibiotics include macrolide esterases and fosfomycin inactivating 
epoxidases (Wright 2005). 
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Figure 1. Mechanisms of β-lactam hydrolysis catalysed by β-lactamases (Wright 2005).  
A: Hydrolysis of ampicillin catalysed by serine β-lactamase. B: Hydrolysis of ampicillin 
catalysed by metallo-β-lactamase.   
 
Transferases are larger and a more diverse group of resistance enzymes compared to 
hydrolysis catalysing enzymes (Wright 2005).  For instance, aminoglycosides are 
inactivated by acetyltransferrases, phosphotransferases and nucleotidyltransferases. 
Other relevant group transfer enzymes include chloramphenicol acetyltransferases and 
lincosaminide nucleotidyltransferases. Covalent modification of the antibiotic by the 
transferase obstructs its binding to the target. Unlike the hydrolysing enzymes all the 
group transfer enzymes are only active in the bacterial cytosol. 
 
In a retrospective observational cohort study conducted by Katchanov et al. (2018) 119 
patients of German university medical centre were found to be colonized or infected by 
Gram-negative carbapenem and multi drug resistant (CR MDR) bacteria during the one 
year study period. The 119 patients with CR MDR bacteria accounted for 0.22% of the 
total patients of the hospital during the study period. The most often found species of the 
CR MDR bacteria were Pseudomonas aeruginosa (66 patients), Klebsiella pneumoniae 
(29 patients) and Acinetobacter baumannii (18 patients). Carbapenemase β-lactamase 
genes were assessed from the CR MDR bacterial isolates of the patients. 60 of the 102 
isolates were found to carry a carbapenemase enzyme gene. 
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2.1.3 Membrane permeability in antibiotic resistance 
 
The third antibiotic resistance strategy is to decrease the intracellular antibiotic 
concentration in bacterium by reducing the net flux through the outer membrane. GNB 
decrease the antibiotic outer membrane net flux by two mechanisms (Cag et al 2016). The 
penetration of antibiotics through the outer membrane can be reduced or the efflux of the 
antibiotics back to the extracellular space can be increased. Efflux pumps of the outer 
membrane play a key role in the antibiotic resistance mediated by antibiotic efflux. Porins 
are critical for the outer membrane permeability of many antibiotics.   
 
Porins in antibiotic resistance 
 
The outer membrane of GNB is normally only slightly or non-permeable to hydrophilic 
substances (Nikaido 2003). Thus, bacteria express multiple channel-forming proteins that 
allow the influx of important hydrophilic substances, like nutrients. Some of these 
channels are substrate-specific while some allow non-specific diffusion of hydrophilic 
solutes. These non-specific channels are called porins. The porins are likely important for 
outer membrane permeation of small antibiotics like β-lactams and fluoroquinolones, 
while large and hydrophobic antibiotics reach the intracellular space by diffusing across 
the lipid bilayer of the outer membrane. 
 
The typical porin structure is a water filled β-barrel channel through the outer membrane 
to the periplasmic space (Patridge et al. 2015). Although porins are non-specific they 
often have general substrate preferences regarding size and charge of the substrate 
(Nikaido 2003). GNB often express multiple types of porins with different substrate 
preferences. For instance, E. coli expresses the following porins: OmpF, OmpC and 
PhoE. Porins and especially lack of them plays also an important role in the intrinsic 
antibiotic resistance of many Gram-negative species. For instance, high intrinsic 
resistance of P. aeruginosa to many antibiotics is partly mediated by the slow penetration 
of its main porin OprF. 
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Change in porin-mediated permeability can cause resistance to antibiotics for which 
porins are a relevant route across the outer membrane (Nikaido 2003). Three antibiotic 
resistance mechanisms concerning porins have been encountered clinically. Porin 
expression can be lost or reduced, expressed porin can be replaced by another one and 
porin function may be altered by mutation (Delcour 2009; Patridge et al. 2015). Mutations 
often occur in the L3 loop of the porin structure which folds into the channel and forms a 
narrowing (Nikaido 2003; Delcour 2009). GNB species for which altered porin function 
or expression mediated antibiotic resistance has been encountered include, for example, 
E. coli, P. aeruginosa, Neisseria gonorrhoeae, Enterobacter aerogenes and K. 
pneumoniae. 
 
In the study conducted by Hasdemir et al. (2004) 18 different multi drug resistant K. 
pneumoniae strains were isolated from hospital patients in Turkey. The susceptibility of 
K. pneumoniae strains to 10 antibiotics with and without efflux pump inhibitor was 
measured and expression levels of efflux protein AcrA and porins OmpK35 and OmpK36 
were determined. Interestingly 12 of 18 strains did not express OmpK35 in a low 
osmolarity medium unlike the reference strain ATCC 11296. Also, in two strains the 
expression level of OmpK35 was lower compared to the reference strain. However, 
OmpK36 was expressed in all multi drug resistant strains in both high and low osmolarity 
mediums in similar levels to reference strain. The absence of OmpK35 expression, one 
of the two major porins of K. pneumoniae, in the multi drug resistant strains and 
simultaneous normal expression of the OmpK36 may be explained by the results of 
Domenech-Sanchez et al. (2003). Domenech-Sanchez et al. found out that MIC values of 
five antibiotics, belonging to the cephalosporins and cephamycins, were at least four 
times lower in a K. pneumoniae strain that expressed only OmpK35 compared to strain 
that expressed only OmpK36. MIC values of the other tested antibiotics were the same or 
two times lower in the strain expressing only OmpK35 compared to the strain expressing 
only OmpK36. Thus, possibly the selective pressure by cephalosporins has caused the 
evolution of only OmpK36 expressing multi drug resistant K. pneumoniae strains.  
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A study by Clancy et al. (2013) shows the effect of porin mutations on antibiotic efficacy. 
23 strains of sequence type 258 K. pneumoniae were isolated from bloodstream samples 
of different patients. All of the strains carried the KPC-2 β-lactamase gene and 18 of the 
23 strains carried also an ompK36 mutation. Seven of the 18 mutations were in the 
promoter and the rest were on the ompK36 gene itself. The seven strains carrying 
promoter mutation and eight strains with similar six base pair insertion mutation (aa134-
135 GD) had significantly higher MIC values of doripenem compared to other three 
strains with different mutations and five wild type strains. The KPC-2 β-lactamase 
expression level of the strains was not associated with the doripenem MIC values. The 
strains carrying the promoter mutation had significantly lower OmpK36 expression level 
compared to wild type strains and strains with other mutations. The strains with aa134-
135 GD mutation did not show diminished expression of OmpK36. OmpK36 mutations 
had no effect on MIC of the second tested antibiotic colistin. As these results show, porin 
mutations can affect antibiotic susceptibility of GNB by decreasing the porin expression 
or by mechanisms related to reduced porin function. 
 
Efflux pumps and antibiotic resistance 
 
The second mechanism of GNB to decrease the intracellular antibiotic concentration is 
the efflux, which is mediated by efflux pump proteins. Just like the porins, bacterial efflux 
pumps play a role in both intrinsic and acquired antibiotic resistance (Blair et al. 2014; Li 
et al. 2015). Most of the bacteria express a large number of different efflux pumps, 
however, usually only a few of those mediate antibiotic resistance (Piddock 2006). 
Substrate specificity of the bacterial efflux pumps varies from specific to broad (Blair et 
al. 2014). The origin of bacterial efflux pumps dates back to the time before medical use 
of antibiotics and it is thought that the original function of efflux pumps has been the 
efflux of intracellular metabolites and harmful compounds of the environment (Piddock 
2006).  
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Resistance nodulation division (RND), multidrug and toxic compound extrusion 
(MATE), major facilitator superfamily (MFS), small multidrug resistance (SMR) and 
ATP-binding cassette (ABC) are all classes of bacterial efflux pumps with antibiotic 
efflux mediating members (Li et al. 2015) (Figure 2). These classes differ in structure, 
energy source of efflux, location in the bacteria and substrates. RND is clinically the most 
important antibiotic resistance mediating class of efflux pumps in GNB (Blair et al. 2014). 
ABC transporters use ATP as the energy source of the efflux while other classes are 
secondary transporters, most of which use proton motive force as the energy source (Li 
et al. 2015). RND transporters function as a part of a tripartite structure which spans from 
the inner membrane through the periplasmic space to the outer membrane allowing the 
extrusion of the substrate to the extracellular space. Most members of the other classes 
have a single-component structure and are located only in the inner membrane of the 
bacterium allowing only extrusion of substrate from the cytosol to the periplasmic space. 
This functional difference is probably one reason for the prominent role of the RND 
transporters in the antibiotic resistance. 
Figure 2. Schematic picture of structures and locations of different efflux pump classes 
in the membranes of Gram-negative bacteria (Du et al 2018).  Members of ABC, MFS, 
MATE and SMR efflux pump families usually function as independent units and pump 
substrates (red hexagons) from the cytosol to the periplasmic space. Efflux pumps of the 
RND family usually function as a part of a tripartite efflux complex and pump substrates 
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from the periplasmic space to the extracellular space. Also more uncommon tripartite 
efflux complex with ABC-transporter is shown at the right. 
 
RND pump mediated antibiotic resistance is heavily dependent on the antibiotic’s outer 
membrane permeability (Li et al. 2015). Thus, the physicochemical properties of the 
antibiotic, the species of the bacteria and the porin profile of the outer membrane can 
affect the efficacy of efflux. If the antibiotic flux through the outer membrane is rapid the 
efflux pumps cannot outweigh the influx and therefore even the overexpression of efflux 
pumps will not generate significant resistance. However, if the antibiotic permeates the 
outer membrane of the bacterium slowly, overexpression of the efflux pumps can cause 
great increase in the resistance. Thus, overexpression of the efflux pumps generates 
higher level of resistance in bacterial species with low outer membrane permeability, like 
in P. aeruginosa and against antibiotics which penetrate the outer membrane slowly, like 
erythromycin. 
 
Clinically relevant GNB species for which the antibiotic resistance caused by 
overexpression of efflux transporter is common include P. aeruginosa, A. baumannii, 
Burkholderia pseudomallei, Salmonella, Campylobacter jejuni and E. coli (Blair et al. 
2014). Clinically relevant RND efflux pumps in Gram-negative species include AcrAB-
TolC of E. coli and Salmonella enterica, MexAB-OrpM of P. aeruginosa and CmeABC 
of C. jejuni for example. Efflux pumps of RND family are mainly chromosomally 
encoded but there are also some clinically relevant plasmid encoded efflux proteins, like 
fluoroquinolone resistance mediating qepA of the MFS-family (Yamane et al. 2007, Li et 
al. 2015). Also increase in the prevalence of RND transporter carrying plasmids and the 
following dissemination is an unsettling future scenario (Li et al. 2015). 
 
The overexpression of the efflux pump and the following antibiotic resistance can result 
from mutations in the efflux pump expression regulating genes, like in local repressor, 
global regulator and transcription factor genes (Piddock 2006; Blair et al. 2014). Also, 
mutations in the promoter area of the efflux pump gene can result in overexpression and 
antibiotic resistance. In a study conducted by Shigemura et al. (2015) 105 strains of P. 
aeruginosa were isolated from urinary tract infection patients of three hospitals in Japan. 
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26.7%, 11.4%, 41.9% and 38.1% of the P. aeruginosa strains were increasingly 
expressing mexB, mexC, mexE and mexY RND efflux pump genes, respectively, 
compared to the control strain PAO1. Significant association was found between 
levofloxacin resistance and overexpression of mexC. However, no other statistically 
significant associations were found with gene expressions of the four efflux pump genes 
and susceptibilities to nine antibiotics of different classes.  
 
2.2 RND efflux pump structure and function  
 
As mentioned earlier RND transporters are the most relevant antibiotic efflux-proteins of 
GNB (Blair et al. 2014). RND transporter complex AcrAB-TolC is the most effective 
antibiotic efflux complex of wild type E. coli. AcrAB-TolC has an extremely wide 
substrate range, including members from practically all classes of antibiotics with the 
exception of aminoglycosides (Sulavik et al. 2001; Li et al. 2015). In this chapter the 
structure and function of this most studied member of RND class of efflux transporters is 
shortly covered (Li et al. 2015). 
 
RND transporters are located in the inner membrane of GNB and function as a part of a 
tripartite structure (Li et al. 2015). This three-part efflux complex spans from the bacterial 
cytosol through the periplasmic space to the extracellular space and is composed of the 
RND pump, a periplasmic adaptor protein and an outer membrane channel. All of these 
components of the RND pump complex are necessary for its efflux function (Ma et al. 
1995; Fralick 1996; Anes et al. 2015). For instance, RND pump complex AcrAB-TolC is 
composed of the RND pump AcrB, periplasmic adaptor protein AcrA and outer 
membrane channel TolC (Li et al. 2015). The stoichiometry of these components is 3:6:3, 
thus, AcrB and TolC are homotrimers and AcrA is a hexamer in the AcrAB-TolC 
complex (Tikhonova et al. 2011; Du et al. 2014; Wang et al 2017). 
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AcrB, the RND pump of the complex, is mainly located in the inner membrane and in the 
periplasmic space, however, a small part of it spans also to the cytosol (Murakami et al. 
2002; Du et al. 2018). The second part of the complex, AcrA is located in the periplasmic 
space where it surrounds and interacts with periplasmic parts of the AcrB and TolC 
(Hinchliffe 2013; Anes et al. 2015). The most peripheral part of the complex is TolC, 
which is located in the outer membrane. TolC connects the periplasmic part of the AcrAB-
efflux complex to the extracellular space. Based on the results by Tikhonova et al (2011), 
AcrB binds to the TolC directly in the periplasmic space and AcrA is not required for the 
interaction. However, the periplasmic adaptor protein AcrA probably stabilizes the 
interaction between AcrB and TolC (Hinchliffe et al. 2013). AcrA is also required for 
sealing the periplasmic part of AcrAB-TolC (Wang et al 2017). In addition to the AcrAB-
TolC complex, TolC functions as an exit duct also in other tripartite efflux pump 
complexes of E. coli, for instance in MacAB-TolC and EmrAB-TolC complexes 
(Hinchliffe et al. 2013). Simplified illustration of the AcrAB-TolC structure is shown in 
the Figure 3.  
Figure 3. Simplified side view picture of the AcrAB-TolC efflux pump complex 
(Murakami et al 2006). In the picture blue AcrB proteomer is in the open conformation 
and the red proteomer is in the extrusion conformation. Orange hexagon represents the 
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substrate and solid arrows represent the efflux path of the substrate. Dotted arrows 
represent the proton influx. 
 
AcrB is a homotrimer with the three proteomers in different conformations in the ligand 
binding state (Murakami et al. 2006). Rotation of the trimer conformers seems to mediate 
the efflux mechanism. The three proteomers of AcrB are in a ring-like formation and form 
a short tube looking protein (Murakami et al 2002). The three proteomers are linked to 
each other in the periplasmic end of the protein by long hairpin structures which 
presumably provide strong interaction. Compared to the periplasmic end the proteomers 
seem to be more loosely packed in the transmembrane part of AcrB. Inside the proximal 
periplasmic AcrB the three proteomers form a cavity with around 30Å diameter called 
the central cavity. The base of the central cavity is presumably formed by the inner 
membrane and the side walls and the top are formed by the three proteomers (Murakami 
et al 2002; Eicher el al. 2012). In the distal periplasmic AcrB the proteomers form a funnel 
structure (Murakami et al 2002). A close homolog transporter with very similar structure 
to AcrB is found in all members of Enterobacteriaceae and for instance in P. aeruginosa 
(MexB) (Li et al. 2015). 
 
Inside each AcrB proteomer is a substrate tunnel which leads from the entrance channels 
on the proximal periplasmic surface of the proteomer to the inner surface of the funnel 
structure at the distal end of the AcrB (Murakami et al. 2006; Nakashima et al. 2011; 
Eicher el al. 2012). The different conformations of the proteomer change the diameter of 
this substrate tunnel at different parts of it. The tunnel is not thoroughly open at any 
conformation, thus conformation changes are needed for substrate to traverse the whole 
tunnel.  
 
Substrates have access to inside of the AcrB proteomer from at least two entrance 
channels, possibly three, when the proteomer is in the open conformation (O-
conformation, or also called access conformation) (Nakashima et al. 2011). One of the 
two entrance channels is just above the inner membrane while the second one is further 
away in the periplasmic part of the AcrB. The third putative entrance channel is located 
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on the surface of the central cavity. Substrate entrance channels lead to the two substrate 
binding sites (Nakashima et al. 2011; Eicher el al. 2012). These two binding sites are 
close to each other separated by the switch loop structure. The diameter and shape of 
these two binding sites and the conformation of the switch loop between them changes at 
the different conformations of the proteomer. Both polar and hydrophobic amino acids 
are located at both binding sites, thus allowing multiple types of interactions with 
substrates (Murakami et al. 2006; Nakashima et al. 2011). However, at least in the distal 
binding site most of the amino acids are hydrophobic (Murakami et al. 2006). From the 
proximal binding site through the distal binding site the substrate tunnel leads to the 
extrusion channel which connects the binding sites to the funnel (Nakashima et al. 2011; 
Eicher el al. 2012). The funnel eventually leads to the extra cellular space through the 
TolC pore. 
 
The prevailing theory of AcrB efflux mechanism is based on the three conformations of 
the proteomers (Murakami et al. 2006; Nakashima et al. 2011; Eicher el al. 2012). The 
conformations are open conformation, binding conformation (also called tight or T-
conformation) and extrusion conformation (also called loose or L-conformation). Each of 
these conformations mediates one of the three steps in the efflux mechanism. These three 
conformations are concertedly rotating in the trimer so that every proteomer is in a 
different conformation and phase of the efflux mechanism. Simplified illustrations of the 
conformations and efflux mechanism of AcrB proteomer and trimer are shown in the 
Figures 4 and 5. 
Figure 4. Top-view illustration of the concerted efflux mechanism of AcrB protein (Du 
et al 2018). The three proteomers are in different tints of blue and the substrates are 
represented by the orange hexagons. AcrB transfers the substrates from the periplasmic 
space (outside the protein) to the funnel structure (in middle of the proteomers) which 
connects the substrate extrusion pathway to the TolC component of the AcrAB-TolC 
efflux complex.    
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Figure 5. Illustration of the three different conformations of the AcrB proteomer 
mediating the efflux process (Nakashima et al 2011). AcrB substrate is represented as 
violet molecule. On the left, the access (open) conformation in which the substrate moves 
from the periplasmic space to the proximal binding site through one of the three entrance 
channels. Next, on the right, the binding conformation in which the substrate moves to 
the distal binding site. Movement is caused by the conformation changes of the switch 
loop and proximal and distal binding sites. Switch loop is located between the two binding 
sites. On the top is the extrusion conformation which mediates the last step of the efflux 
process. In the extrusion conformation distal binding site shrinks and squeezes the 
substrate out of the proteomer to the funnel-like opening on the top of the AcrB protein. 
 
In the open conformation the substrate enters to the proteomer from an entrance channel 
(Murakami et al. 2006; Nakashima et al. 2011; Eicher el al. 2012). In this conformation 
the distant binding site is shrinked and the switch loop provides a steric hindrance to 
distant binding site access (Nakashima et al. 2011; Eicher el al. 2012). Thus, in the open 
conformation only low molecular mass substrates have an access to the distant binding 
site and the high molecular mass substrates bind to the proximal binding site. In the 
binding conformation the distant binding site expands enhancing the substrate binding. 
Also the switch loop conformation changes forcing the high molecular mass substrates to 
the distant binding site from the proximal binding site. In the extrusion conformation the 
extrusion channel to the funnel opens and the channel to the entrance channels closes 
(Murakami et al. 2006; Nakashima et al. 2011; Eicher el al. 2012). Also the conformation 
of distant binding site shrinks pushing the substrates to the extrusion channel. These 
changes squeeze the substrate from the distant binding site to the AcrB funnel structure 
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in the distant head of the protein. From the funnel through the TolC pore to the 
extracellular space the path is common to substrates of the all three proteomers 
(Murakami et al. 2006). It is speculated that AcrA mediates the conformation changes of 
AcrB proteomers to the TolC and causes the synchronized opening of the TolC pore 
(Wang et al 2017; Murakami et al. 2006). Energy for the substrate efflux by AcrB is 
derived from proton influx from the periplasmic space to the cytosol (Li et al. 2015).  
 
In addition to the three necessary components of the AcrAB-TolC, more recently a fourth 
component of the efflux complex was found by Hobbs et al. (2012). It was named as 
AcrZ. AcrZ seems to interact with the RND pump AcrB of the complex. This small 49 
amino acids protein affects only efflux of some substrates by AcrAB-TolC. It is suggested 
that the AcrZ adjusts recognition and binding of certain substrates by AcrB by 
conformation modulation. 
 
The large volume of AcrB binding sites and the high quantity of interaction mediating 
residues in the binding sites are likely important factors for the wide substrate range of 
AcrAB-TolC complex (Murakami et al. 2006). This allows different substrates to bind to 
different residues in the binding sites (Murakami et al. 2006; Nakashima et al. 2011). In 
fact, in molecular dynamic simulations (MD) conducted by Vargiu and Nikaido (2012) 
the nine simulated substrates were found to interact with 25 different amino acids in the 
distal binding site. One or multiple hydrophobic groups in the molecular structure is a 
common property of AcrB substrates (Nikaido et al. 1998, Li et al. 2015). This common 
property of substrates might be key for wide substrate range of multidrug efflux pumps 
as suggested by Neyfakh (2002). Because of the hydrophobic groups, the substrate 
antibiotics are not strongly stabilized by the water molecules of the cytosol, thus the 
energy barrier to overcome in the efflux pump binding is relatively low compared to 
binding of hydrophilic substrates to enzymes (Neyfakh 2002; Li et al. 2015). Because of 
this relatively low energy barrier of binding the binding sites of AcrB can be large and 
polyspecific. 
 
19 
 
2.3 Inhibitors of RND efflux pumps 
 
One strategy to obstruct the function of above described RND transporters of Gram-
negative pathogens is small molecule efflux pump inhibitors (EPIs), which would be used 
as a combination therapy with antibiotics. EPIs could restore the effectivity of antibiotics, 
which RND transporter mediated resistance has made clinically non-useful. EPIs could 
possibly even make some of the antibiotics currently used only against Gram-positive 
species effective also against Gram-negative pathogens (Li et al 2015; Mahmood et al 
2016). In addition to the antibiotic potentiating effect, EPIs could possibly prevent 
occurrence of bacterial resistance mutations, biofilm formation and even inhibit toxin 
mediated virulence of some enteropathogenic species (Opperman and Nguyen 2015). 
However, despite multiple efforts still no EPI against bacterial RND efflux pumps has 
reached the clinical phase of drug development. Multiple EPI drug candidates have been 
studied in vivo, in vitro and in silico by using for instance efflux pump deleted mutant 
strains, substrate competition assays, RND substrate dye accumulation, isothermal 
titration calorimetry (ITC), X-ray crystallography, docking and MD simulations (Li et al 
2015; Opperman and Nguyen 2015; Mahmood et al 2016). Still toxicity, 
pharmacokinetics, spectrum of activity, potency and outer membrane permeability related 
problems have prevented progress of candidates to the clinical phase (Opperman and 
Nguyen 2015). Also, the wide substrate range and extensiveness of the substrate binding 
site of RND transporters add difficulty to EPI development because there are no clear 
limits for the physiochemical properties of EPIs or RND substrates (Mahmood et al 
2016). In the following paragraphs four known inhibitors of the AcrB RND efflux pump 
of E. coli will be presented in chronological order of discovery, which is followed by 
broader group of quinolone derivates with documented EPI activity. 
 
2.3.1 Phenyl-argine-β-naphtylamide 
 
The first notable effort to develop an EPI against RND efflux pumps reaching the 
preclinical drug development phase was phenyl-argine-β-naphtylamide (PAβN) (Figure 
6) (Aron and Oppermann 2018). PAβN, also known as MC-207,101, was found as a result 
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of compound collection screening against P. aeruginosa strains overexpressing Mex 
RND efflux pumps (Renau et al 1999). Later it was found out that PAβN also inhibits 
AcrAB-TolC of E. coli in addition to MexAB-OrpM, MexCD-OrpJ and MexEF-OrpN 
RND pumps of P. aeruginosa (Lomovskaya et al 2001). Intrinsic MIC values of 400 and 
256 μg/ml have been obtained for PAβN in wild type E. coli strains and the MIC value 
has been found to be dependent on the expression level of acrAB in E. coli (Kern et al 
2006; Matsumoto et al 2011). PAβN has no effect on the proton gradient of the inner 
membrane and thus the inhibition of RND efflux pumps is not based on de-energization 
(Lomovskaya et al 2001). However, it was found out that PAβN also increased the outer 
membrane permeation of P. aeruginosa, in addition to its EPI activity. Based on the 
results of Matsumoto et al (2011), PAβN may have similar permeabilizing effect also on 
E. coli. Thus, the experiments measuring the EPI activity of PAβN should be done in 
1mM Mg2+ which minimizes the permeating effect (Opperman and Nguyen 2015). After 
all, it is not completely clear how significant the outer membrane effect of PAβN is 
regarding the increased antibiotic susceptibility, but it is likely strain and species 
dependent (Lomovskaya et al 2001; Matsumoto et al 2011). 
Figure 6. Molecular structure of efflux pump inhibitor Phenyl-Argine-β-naphtylamide 
(PAβN) (Renau et al 1999). 
 
The initial in vivo experiments with a close homolog of the PAβN gave promising results 
(Renau et al 1999). An N-methyl derivate of PAβN was used in the in vivo experiments 
because PAβN is not stable in mouse, rat or human serum. In a murine neutropenic thigh 
model, combination of PAβN derivate with levofloxacin resulted in 3-log reduction in P. 
aeruginosa colony-forming units (cfu) compared to the no treatment controls and only 
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levofloxacin or N-methyl PAβN treated mice. 30 mg/kg dose was used for both 
levofloxacin and PAβN derivate in the experiment. However, in pharmacokinetic 
experiments done with rats, the active PAβN derivates were found to accumulate to 
kidney increasing the possibility for toxicity (Watkins et al 2003). It was found out that 
the dicationic nature of the PAβN derivates was likely causing the accumulation. 
Unfortunately, the dicationic structure was also essential for the EPI activity of the 
derivates. Because of these pharmacokinetic and toxicity problems development of PAβN 
as a drug candidate was suspended (Lomovskaya and Bostian 2006). Nevertheless, PAβN 
is still used as a laboratory reagent to study RND pump mediated bacterial efflux. 
 
Based on the results of Lomovskaya et al. (2001), it seems likely that PAβN is both 
substrate and inhibitor of RND efflux pumps. PAβN inhibits the efflux of different RND 
substrates to different extent. This may be related to substrates binding to the different 
subsites within the substrate binding site. The mechanism of AcrB efflux inhibition by 
PAβN has been studied with computational methods by Vargiu and Nikaido (2012). 
Based on their MD-simulations, PAβN binds to substrate binding site of AcrB with higher 
affinity than average substrate. However, the affinities of simulated substrates are still 
quite similar to affinity of PAβN and some substrates like nitrocefin bind with even higher 
affinity than PAβN. These findings suggest that inhibition mechanism of PAβN is not 
based on high affinity binding resulting in hindrance to substrate binding and AcrB 
conformation changes. Nevertheless, in the simulations there was one clear difference in 
the AcrB binding of normal substrates compared to PAβN. Unlike the other substrates 
PAβN interacted with the switch loop in addition to the moieties of the distal binding site. 
These results suggest that inhibition mechanism of PAβN may be related to the straddling 
of the switch loop. 
 
As described above PAβN inhibits the function of E. coli and P. aeruginosa RND efflux 
pumps. The effect of PAβN on antibiotic efflux of other pathogenic bacteria has also been 
studied. Based on the results of Panek et al. (2006), PAβN had very limited effect on A. 
baumannii RND efflux pump AdeABC. However, PAβN had also an AdeABC 
independent effect on clarithromycin and rifampicin susceptibility of A. baumannii, 
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which was probably based on the increased outer membrane permeability. In a study 
conducted by Hannula and Hänninen (2008) PAβN increased susceptibility of C. jejuni 
and Campylobacter coli to erythromycin and rifampicin but not to other CmeABC efflux 
pump substrates. Unfortunately, the outer membrane effect of PAβN was not taken in to 
consideration by Hannula and Hänninen, which reduces reliability of the conclusions 
regarding the effect of PAβN on CmeABC. PAβN increased also susceptibility of Vibrio 
cholerae to the antibiotics which are RND pump substrates (Bina et al 2009). 
 
2.3.2 1-(1-Naphthylmethyl)-piperazine 
 
EPI 1-(1-Naphthylmethyl)-piperazine (NMP) (Figure 7) was found by screening aryl 
piperazines with levofloxacin against AcrAB and AcrEF overexpressing E. coli strains 
(Bohnert and Kern 2005). With 100 μg/ml concentration NMP was found to reduce MIC 
values of levofloxacin, linezolid, clarithromycin and chloramphenicol for four times or 
more in AcrAB and AcrEF overexpressing E. coli strains but not in the AcrAB and AcrEF 
deficient strain. Also in a following study with clinical E. coli isolates, NMP was found 
to reduce MIC50-values of levofloxacin, linezolid, rifampicin and ethidium bromide by 
four times or over in most of the studied isolates (Kern et al 2006). The intrinsic MIC 
value of NMP is 400 μg/ml with E. coli (Bohnert and Kern 2005). Unlike PAβN the 
intrinsic MIC value of NMP is not affected by expression of efflux pumps, suggesting 
that NMP is not a substrate of RND pumps like PAβN. Also results from Schuster et al 
(2014) suggest that NMP itself is not a substrate of AcrB or it is a very poor one.  
Figure 7. Molecular structure of efflux pump inhibitor 1-(1-Naphthylmethyl)-piperazine 
(NMP) (Vargiu et al 2014). 
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AcrB inhibition mechanism of NMP has been studied with MD-simulations in the same 
study by Vargiu and Nikaido (2012) as the PAβN inhibition mechanism. Based on the 
MD-simulations, the binding site and proposed inhibition mechanism of NMP were found 
to be relatively similar to those of PAβN. In one simulation NMP bound to the proximal 
binding site of AcrB, however, in most simulations NMP interacted with the distal 
binding site of AcrB as expected. Nevertheless, in all simulations NMP interacted with 
the tip of the switch loop and straddled it, thus suggesting impaired switch loop movement 
based inhibition mechanism similar to PAβN. If both NMP and PAβN inhibit the AcrB 
function by the same switch loop straddling mechanism, it is interesting how there are so 
evident differences in their effect on the efflux of AcrB substrates. Also, the results of 
random mutagenesis study done with AcrB overexpressing E. coli suggests different 
binding site for NMP (Schuster et al 2014). The G141D N282Y double mutation in the 
distal part of the AcrB distal binding site was the only mutation found to reverse the EPI 
activity of NMP. This double mutation was able to reverse the EPI activity of NMP with 
linezolid and in some assays with levofloxacin and Hoechst 33342 (H33342) but not with 
other AcrB substrates. However, none of the mutations was found to reverse the EPI 
activity of PAβN, indicating difference in the AcrB inhibition mechanisms of these EPIs. 
All in all, these results by Schuster et al 2014 and Vargiu and Nikaido (2012) seem to 
suggest different binding sites for these EPIs in the substrate binding sites of AcrB.  
 
For its EPI-effect, NMP has been used at 100 μg/ml concentration while PAβN requires 
only 25μg/ml concentration (Bohnert and Kern 2005; Kern et al 2006). However, no 
efflux pump inhibition independent mechanisms, like the outer membrane effect of 
PAβN, has been found with NMP. The RND substrate specificities of NMP and PAβN 
differ. NMP increased susceptibility of E. coli clinical isolates to ethidium bromide much 
more effectively than PAβN (Kern et al 2006). On the other hand, PAβN increases 
susceptibility of E. coli more to pyronin Y, clarithromycin and rifampicin compared to 
NMP. However, the difference in effect on rifampicin and clarithromycin susceptibility 
may be related to the outer membrane effect of PAβN. 
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NMP has not been further developed towards use as an EPI-drug, probably because of its 
likely toxic serotonin agonist properties (Zechini and Versace 2009). It is still widely used 
as a reagent in RND efflux pump research, like PAβN (Opperman and Nguyen 2015). 
Thus, activity of NMP has been studied with multiple bacteria and efflux transporters in 
addition to E. coli and AcrB. Panek et al. (2006) showed that NMP had  AdeB RND efflux 
pump dependent and independent effects on AdeB substrate antibiotic susceptibility of 
A. baumannii. NMP and PAβN had clearly different effects on the antibiotic susceptibility 
of A. baumannii. NMP increased susceptibility of C. coli and C. jejuni to same antibiotics 
as PAβN (erythromycin and rifampicin), but to lower extent (Hannula and Hänninen 
2008). 100μg/ml and 50μg/ml concentrations of NMP and PAβN were used for 
determining the EPI-effect on the MIC values of antibiotics with C. coli and C. jejuni. In 
V. cholerae intrinsic MIC of NMP was found to be 600μg/ml and independent of RND 
pump expression level as in E. coli (Bina et al 2009). NMP also increased the 
susceptibility of V. cholerae to the same antibiotics as PAβN with some differences in the 
susceptibility levels. 
 
2.3.3 D13-9001 
 
Pyridopyrimidine EPI D13-9001 (Figure 8) has been developed by the same researchers 
as the previously presented PAβN (Nakayama et al 2003a). The initial hit compound 
leading to the development of D13-9001 was found by high-through put screening of 
levofloxacin-potentiating compounds in MexAB-OrpM overexpressing P. aeruginosa 
strain in 2003. The initial hit compound had poor physicochemical properties for a drug 
molecule, which led to optimization regarding its solubility, albumin binding, in vitro and 
in vivo efficacy and toxicity (Nakayama et al 2003a; 2003b; 2004a; 2004b; Yoshida et al 
2006a; 2006b; 2007). This extensive optimization resulted D13-9001 (Yoshida et al 
2007). In lethal pneumonia model with rats, D13-9001 was found to increase 
susceptibility of P. aeruginosa (PAM1020) to aztreonam. D13-9001 was also found to 
potentiate levofloxacin in vitro with MexAB-OrpM overexpressing strain. The lethal dose 
of D13-9001 for mouse was found to be over 100mg/kg. Later D13-9001 was found to 
also have EPI activity against AcrB of E. coli (Matsumoto et al 2011; Nakashima et al 
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2013). Unlike PAβN, D13-9001 is not substrate of AcrB or it is very poor one. The 
intrinsic MIC value of D13-9001 is over 64 μg/ml in wild type E. coli and with 32 μg/ml 
concentration it caused four-fold reduction of ciprofloxacin and erythromycin MICs 
(Matsumoto et al 2011). The decrease in ciprofloxacin and erythromycin MICs was not 
seen in acrB or tolC deleted mutants of E. coli. 
Figure 8. Molecular structure of efflux pump inhibitor D13-9001 (Nakashima et al 2013). 
 
D13-9001 is the first EPI which has been cocrystallized with an RND efflux pump 
(Nakashima et al 2013). Structures of D13-9001 bound to the close homologs AcrB and 
MexB were obtained by Nakashima et al in 2013, six years after the development of D13-
9001. Based on these X-ray crystallography results, Nakashima et al were able to 
determine that in both RND efflux pumps D13-9001 binds to the same area in close 
proximity of the distal binding site. The lipophilic part of D13-9001 binds to a cavity 
which branches off from the distal binding site (Figure 9). This cavity structure, also 
called hydrophobic trap, is formed by multiple phenylalanine residues and it doesn’t form 
direct interactions with the efflux pump substrates. The volume of this hydrophobic trap 
was found to be critical for binding and efflux inhibition effect of D13-9001. The 
hydrophilic parts of the D13-9001 interact with the hydrophilic side chains of the distal 
binding site. Based on ITC measurements, D13-9001 binds to AcrB and MexB with high 
affinity. Binding energy of D13-9001 was found to be around twice the measured binding 
energies of substrates minocycline and doxorubicin. Based on these results Nakashima et 
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al (2013) propose that D13-9001 inhibits the efflux mechanism of AcrB by preventing 
the conformation changes related to the functional rotation mechanism of AcrB.  
 
 
Figure 9. Cutaway view of the distal binding site of AcrB (Nakashima et al 2013). Distal 
binding site is defined by the violet line and the hydrophobic trap, which branches off 
from the binding site, is defined by the cyan line. Binding sites of two substrate molecules 
minocycline (blue) and doxorubicin (green) and inhibitor D13-9001 (yellow) are also 
shown in the picture. 
 
Although preclinical development of D13-9001 advanced to as far as determination of 
pharmacokinetic properties with monkeys, this project was still eventually terminated 
before the clinical stage (Yoshida et al 2007, Aron and Opperman 2018). Reason for the 
discontinuation was probably the lack of EPI activity against MexY RND efflux pump of 
P. aeruginosa (Yoshida et al 2007). Inactivity against MexY limits the usefulness of this 
EPI against its original target P. aeruginosa (Yaguchi et al 2015). The reason for the 
inactivity against MexY is the narrower hydrophobic trap of this efflux pump, which 
causes steric hindrance to D13-9001 binding (Nakashima et al 2013). 
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2.3.4 MBX2319 
 
Pyranopyridine EPI MBX2319 (Figure 10) was found by screening compounds that act 
synergistically with ciprofloxacin against E. coli (Opperman et al 2014). In the follow-up 
studies the mechanism turned out to be based on AcrB inhibition. It is clearly the most 
potent of the EPIs presented by far. In wild type E. coli MBX2319 decreased MIC values 
of ciprofloxacin, levofloxacin and piperacillin 2, 4 and 8 fold with 12.5μM (5.1 μg/ml) 
concentration. In tolC and acrB deleted mutants it had no effect at all on ciprofloxacin´s 
MIC and no over two-fold changes were observed with levofloxacin and piperacillin. The 
intrinsic MIC value of MBX2319 is over 100 μM (40.95 μg/ml) in wild type and AcrAB-
TolC deficient E. coli strains. MBX2319 has neither effect on the inner membrane proton 
gradient nor on the outer membrane permeability of E. coli. MBX2319 shows EPI activity 
also in other members of the Enterobacteriaceae family and to some extend in P. 
aeruginosa. 
 
MBX2319 has good drug-like properties regarding molecular weight (409,54), calculated 
logP (4,03), number of hydrogen bond donors and acceptors (0 and 5), polar surface area 
(45.49 Å2) and number of rotatable bonds (2) (Opperman et al 2014). However, 
MBX2319 is very unstable in in vitro metabolic assays with human and murine liver 
microsomes (Nguyen et al 2015). To study the structure-activity relationship and to 
further optimize the properties of the molecule regarding potency, metabolic stability and 
water solubility Nguyen et al (2015) prepared a collection of close MBX2319 analogues. 
One of the synthesized analogues, MBX3135 (Figure 11) shows four-fold reduction in 
MIC values of levofloxacin and piperacillin in E. coli with 0.1 and 0.05 μM 
concentrations making it over 10 times more potent than MBX2319 and around 500 times 
more potent than PAβN (Nguyen et 2015; Sjuts et al 2016). MBX3135 also has improved 
water solubility and metabolic stability in vitro compared to the parent compound 
MBX2319 (Nguyen et 2015). Like MX2319, MBX3135 has no effect on the inner 
membrane proton gradient and it does not increase outer membrane permeability. Still, 
results of Sjuts et al (2016) indicate that MBX3135 causes bacterial RND substrate 
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accumulation also with other mechanism in addition to AcrB inhibition. They suggest 
that MBX3135 inhibits also other RND pumps of E. coli. 
 
AcrB inhibition mechanism of pyranopyridine EPIs has been studied with in silico 
docking, MD-simulations, X-ray crystallography and cryogenic electron microscopy 
methods (Vargiu et al 2014; Sjuts et al 2016; Wang et al 2017). MD-simulations by 
Vargiu et al. (2014) predicted that MBX2319 would bind to the hydrophobic trap 
similarly to D13-9001. However, MBX2319 is a much smaller molecule than D13-9001 
and thus it does not reach the distal binding site, like D13-9001, from the hydrophobic 
trap. Based on the MD-simulations, MBX2319 binds to AcrB with high affinity with the 
interactions to the residues in the hydrophobic trap forming almost 70% of the affinity. 
Based on the simulated affinities, MBX2319 binds to AcrB with slightly lower affinity 
than D13-9001 but with higher affinity than NMP and PAβN. Simulations also suggest 
that at least one of the inhibition mechanisms of MBX2319 would be based on 
conformation changes in the distal binding site caused by its high affinity binding to the 
hydrophobic trap.  
 
In silico results of Vargiu et al (2014) were later confirmed by the X-ray crystallography 
results of Sjuts et al (2016). Sjuts et al (2016) engineered a soluble version of the 
periplasmic AcrB (AcrBper). In the AcrBper protein both MBX2319 and MBX3135 bind 
to the hydrophobic trap. MBX3135 binds to AcrB with even higher affinity compared to 
MBX2319, which likely explains its higher potency. The AcrAB-TolC inhibition 
mechanism of another MBX2319 analog MBX3132 (Figure 12) has been studied with 
cryogenic electron microscopy (Wang et al 2017). The results confirmed that this 
pyranopyridine EPI also binds to the hydrophobic trap. Interestingly, in the presence of 
MBX3132 none of the AcrB proteomers took the open conformation and it caused 
accumulation of the biding conformations in the AcrB trimers. In presence of MBX3132 
over 70% of the AcrB trimers were in homological TTT-conformation making the 
AcrAB-TolC complex non-functional. These results suggest that pyranopyridine EPIs 
prevent the functional conformation rotation of AcrAB-TolC by trapping proteomers to 
29 
 
the binding conformation. While the pyranopyridine EPIs’ inhibition mechanism and in 
vitro activity are relatively well studied they still lack results from in vivo experiments. 
Figure 10. Molecular structure of efflux pump inhibitor MBX2319 (Opperman et al 
2014). 
Figure 11. Molecular structure of efflux pump inhibitor MBX3135 (Sjuts et al 2016). 
 
Figure 12. Molecular structure of efflux pump inhibitor MBX3132 (Sjuts et al 2016). 
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2.3.5 Quinolones 
 
In addition to the above mentioned well characterized EPIs, multiple quinolone derivates 
have been reported to have EPI activity against the AcrAB-TolC efflux complex. 
However, the EPI mechanisms of these quinolone derivates have been less studied 
compared to the above presented EPIs and only by single studies. Results of Vidal-Aroca 
et al (2009) suggest that mefloquine (Figure 13) inhibits AcrB and MexB RND efflux 
pumps of E. coli and P. aeruginosa. Mefloquine causes dose dependent accumulation of 
AcrB substrate ethidium bromide to wild type E. coli with 25 (9.46 μg/ml) and 50 μM 
(18.92 μg/ml) concentrations. 
 
Results by Mallea et al (2003) suggest that 4-alkylamino quinolones also inhibit AcrB 
function. The most potent of the studied 4-alkylamino quinolones, called compound 814 
(Figure 14), causes 16-fold decrease in the MIC value of the AcrB substrate 
chloramphenicol in acrAB-tolC overexpressing E. aerogenes strain. Compound 814 
causes the 16-fold decrease of chloramphenicol MIC at 200 μM concentration which is 
one fifth of its intrinsic MIC. Compound 814 causes also chloramphenicol accumulation 
to acrAB-tolC overexpressing E. aerogenes strain and decreases MIC values of 
norfloxacin and tetracyclin. 
 
The third quinolone derivate showing potential EPI activity against AcrB is 4-alkoxy 
quinolone, called compound 905 (Figure 15) by Chevalier et al (2004). Compound 905 is 
also able to decrease chloramphenicol MIC by 16-fold in acrAB-tolC overexpressing E. 
aerogenes strain. Like compound 814, compound 905 increases accumulation of 
chloramphenicol to acrAB-tolC overexpressing E. aerogenes strain. Compound 905 had 
no significant effect on the chloramphenicol MIC value in tolC and acrA deleted strains, 
supporting the AcrAB-TolC inhibition mediated mechanism. Unfortunately effects of 
mefloquine and 4-alkylamino quinolone compound 814 were not studied in AcrB-
inactivated strains (Mallea et al 2003; Vidal-Aroca et al 2009). Chevalier et al (2004) 
studied the effect of compound 905 also on the outer membrane permeability of E. 
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aerogenes, finding out that it has no outer membrane permeabilizing effect. 
Unfortunately, neither mefloquine’s nor compound 814’s outer membrane 
permeabilizing effect and effect on the inner membrane proton gradient were not studied 
(Mallea et al 2003; Vidal-Aroca et al 2009).  
 
All in all, these quinolone derivates seem to cause intracellular accumulation of AcrB 
substrate antibiotics and increase susceptibility to them. However, these compounds’ 
exact cellular mechanisms are not clear. The role of different AcrAB-TolC components 
and other efflux pumps in addition to the possible outer membrane and proton gradient 
effects should be studied before further conclusions about AcrB inhibition. 
Figure 13. Molecular structure of mefloquine (Merck KGaA 2019a). 
Figure 14. Molecular structure of compound 814 (Mallea et al 2003). 
Figure 15. Molecular structure of compound 905 (Chevalier et al 2004). 
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2.4 Conclusions 
 
Multiple inhibitors of the efflux pump AcrB have been explored and developed since 
1999. These EPIs form a chemically diverse group of compounds with a common 
property of multiple hydrophobic ring structures. Based on in silico simulations and in 
vitro results, these EPIs also bind to different areas within the binding pocket of AcrB 
and have different antibiotic potentiating profiles. Potency of these EPIs has increased 
dramatically from the early EPIs like PAβN and NMP to the latest MBX-compounds. 
Still, despite the extensive optimization projects and promising in vivo efficacy results, 
none of these EPIs has reached the stage of drug development where it would have been 
tested in humans. Nevertheless, EPIs like PAβN and NMP have still turned out to be 
important tools for RND efflux pump research. 
 
It has to be remembered that antibiotic resistance is a broad worldwide phenomenon 
mediated by multiple mechanisms. Thus, EPIs alone would not solve this problem as the 
bacteria have multiple other resistance mechanisms in their arsenal. Still, despite the 
antibiotic target site mutations, enzymatic inactivation of antibiotics and altered outer 
membrane porins the EPIs could be a remarkable way to fight the increasing antibiotic 
resistance among pathogenic GNB. As it is common for multiple antibiotics and antibiotic 
resistance mechanisms it is possible that effective EPIs created by evolution are still to 
be found from the nature. 
 
3. OBJECTIVES OF THE EXPERIMENTAL PART 
 
The objective of this thesis’ experimental part was to develop and validate an EPI 
screening method in 384-well plate (384WP) format for screening new EPIs against 
efflux pumps of E. coli. The E. coli strain (BAA1161), the positive control EPI 
(mefloquine) and the antibiotic (piperacillin) for the screening assay were already 
determined in previous studies by Yrjänheikki (2018). The first objective was to validate 
and miniaturize the screening assay from the 96-well plate (96WP) to 384WP format. The 
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second objective was to conduct a few thousand compounds screen with the developed 
assay to test the newly developed assay and to identify novel EPIs. However, as constant 
difficulties in the miniaturization process were encountered the size of the EPI screen had 
to be reconsidered. The inconsistencies of bacterial growth encountered in the plate 
uniformity and DMSO compatibility assays made a large test screen unreasonable. Thus, 
it was decided that a dramatically smaller screen would be conducted to test the 
functionality of developed assay. Steps of the miniaturization process and development 
of the EPI screening assay are presented in the Figure 16. 
 
Figure 16. Flow chart of the EPI screening assay development and validation process. 
The test screen and follow-up assays with the hit molecules are also included. 
 
 
 
 
 
 
Antimicrobial susceptibility test in 
96WP:
Determination of the MIC values of 
positive control EPI and antibiotic to 
be used in the screen. 
Checkerboard assay in 96WP:
Determination of the synergistic 
effect of antibiotic and EPI against 
the bacterial strain. 
Signal to background assay in 
384WP:
Determination whether the 
absorbance measument is sensitive 
enough method for measuring the 
bacterial growth in 384WP
Antimicrobial susceptibility test in 
384WP:
Determination whether change to 
384WP format has effect on the 
MIC values of positive control EPI 
and antibiotic 
Checkerboard assay in 384WP:
Determination whether change to 
384WP format has an effect on the 
synergistic effect of antibiotic and 
EPI 
Plate uniformity assay in 384WP: 
Determination of possible edge and 
drift effects on the screening plate 
DMSO compatibility assay in 384WP
Determination of the maximal 
acceptable DMSO concentration to 
be used in the EPI screen 
EPI-screen in 384WPs
Dose-response assay in 384WP
Follow-up study with the hit 
compounds found in the screen. For 
verifying the effect detected in the 
screen
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4. MATERIALS AND METHODS 
 
4.1 Bacterial strains and handling 
 
E. coli BAA1161 was chosen as the bacterial strain to be used in the EPI screening based 
on the results of Yrjänheikki (2018). In her M. Sc. thesis Yrjänheikki conducted multiple 
assays including H33342 accumulation (Coldham et al 2010), antibacterial susceptibility 
(CLSI, 2012) and checkerboard assays (Lomovskaya et al 2001) to define an optimal E. 
coli strain, antibiotic and control EPI to be used in the EPI screening assay. E. coli strain 
BAA1161 was purchased from American Type Culture Collection (ATCC). In addition 
to BAA1161, tolC deleted E. coli strain JW5503 was used in the antimicrobial 
susceptibility assays. E. coli BAA1161 was the only bacterial strain used in the other 
assays. JW5503 was used for confirming the role of efflux pumps for tolerance of 
antibiotic used in the screening assay. E. coli strain JW5503 was obtained from National 
BioResource Project (Keio collection).  
 
All the experiments and handling of bacteria was performed in level two laminar hoods 
following aseptic practices with the exception of automated source plate preparation for 
checkerboard assay with Biomek i7 automated workstation. In all the experiments 
passage number of bacteria was constant as following protocol of bacterial culture was 
followed in all the experiments. Main stocks of the bacteria were stored in -80 ᵒC. At least 
once a month, a monthly bacterial working culture (MWC) was prepared from the main 
stock on a Mueller-Hinton agar (MHA) plate and was incubated overnight in 37 ᵒC. After 
overnight incubation in 37 ᵒC MWC was stored in +4 ᵒC and it was used for preparation 
of weekly bacterial working cultures (WWC). WWC was also prepared on a MHA plate 
and was incubated overnight in 37 ᵒC before storing in +4 ᵒC. WWC cultures were used 
for maximum of one week for preparation bacterial overnight cultures (ONC). For the 
experiments only bacteria from ONCs were used. ONCs were prepared 20h before the 
experiment on a MHA plate and were incubated in 37 ᵒC. MHA plates were prepared in 
house. Instead of MHA plates, lysogenic broth (LB) agar slants with 25 μg/ml kanamycin 
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were used for E. coli JW5503 MWCs. LB agar plates with 25 μg/ml kanamycin were 
purchased from Media Kitchen. 
 
In all the experiments bacterial growth was quantitated by absorbance measurement. A 
similar protocol for measuring the absorbance was used in all the experiments. 
Absorbance was measured with Multiskan GO (Thermo Scientific) device at the 
wavelength of 620 nm and before each measurement 5 seconds agitation was applied to 
the plate. Experiments in the 96WP format were done in Nunclon Delta Surface (Thermo 
Scientific) plates and experiments in the 384WP format were done in clear Nunc 384-
well polystyrene plates (Thermo Scientific). During the experiments the plates were 
incubated in a plate thermo-shaker (Biosan) in 37 ᵒC. 96WPs were incubated with 500 
rpm agitation and 384WPs without agitation. 
 
In all experiments 5x105 cfu/ml bacterial concentration was used. To do so initial bacterial 
suspension was prepared from ONC to 0.9% saline solution. Then bacterial concentration 
of this initial suspension was measured with DEN-1B McFarland Densitometer (Biosan). 
Based on the measured concentration of initial bacterial suspension, required volume of 
initial bacterial suspension was diluted with Mueller-Hinton broth (MHB) resulting in 
1x106 cfu/ml bacterial suspension. 1x106 cfu/ml bacterial suspension was diluted to final 
bacterial concentration of 5x105 cfu/ml in all experiments with the treatment solutions. 
 
4.2 Chemicals 
 
Piperacillin (PIP) was chosen to be used as the antibiotic and mefloquine (MEF) was 
chosen to be used as the positive control EPI in the EPI screening assay, based on the 
results of Yrjänheikki (2018). MEF and PIP were purchased from Sigma-Aldrich. 
Dimethyl sulfoxide (DMSO) was produced by VWR international. MHB and MHA were 
produced by LabM. Saline solution (0.9%) and ultrapure water were prepared in house. 
All MEF stock solutions were prepared in DMSO following aseptic techniques and stored 
in -20 ᵒC. All PIP stock solutions were prepared following aseptic techniques in ultrapure 
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water and filter sterilized with polyether sulfone (VWR International) or cellulose acetate 
(VWR International) filter. PIP stock solutions were stored in -20 ᵒC. 
 
4.3 Absorbance signal strength assessment in 384-well plate  
 
Absorbance signal strength assessment assay was conducted in 384WP after the 
antimicrobial susceptibility and checkerboard assays in 96WP format before other assays 
in 384WP format were conducted. Nevertheless, this assay is reviewed first as the 
antimicrobial susceptibility and checkerboard assays of both plate formats are reviewed 
in same sections. Absorbance signal level caused by maximal BAA1161 growth in 
384WP was determined, to decide whether the absorbance measurement is sensitive 
enough method for quantifying the bacterial growth in the 384WP. The assay was 
performed as follows: to half of the 384WP only 50 μl of MHB with 5% of water and 1% 
of DMSO was added. These wells represented the background level of absorbance in the 
wells without bacterial growth. To the other half of the 384WP 25 μl of MHB with 10% 
of water and 2% of DMSO was added. Which was followed by the addition of 25 μl of 
1x106 cfu/ml bacterial suspension. This second half of the plate represented the maximal 
bacterial growth and absorbance to be measured in the 384WP. Absorbance of the wells 
was measured at the time points 0, 8 and 24h. From the 24h time point results signal to 
background and Z-factor were calculated.   
 
4.4 Antimicrobial susceptibility assays for determining the MIC values 
 
MIC values of the antibiotic PIP and EPI MEF were determined to quantitate the intrinsic 
antibacterial effects of these compounds. Intrinsic antibacterial effects of these 
compounds had to be determined before the synergistic effect of these compounds could 
be determined with the checkerboard assay. MIC values of PIP and MEF were determined 
in both 96 and 384WP formats to see whether the plate format has any effect on the 
antimicrobial effect of these compounds.  
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For determining the MIC values of PIP and MEF in 96WP and 384WP formats CLSI’s 
broth microdilution method was followed (CLSI 2012). The concentration which on 
average caused at least 90% inhibition of bacterial growth, based on the absorbance 
measurements, was considered as the MIC value. The MIC value was confirmed by two 
independent experiments. MIC values of PIP and MEF were determined with BAA1161 
strain in 96 and 384WP formats. With JW5503 strain only MIC value of PIP was 
determined in 96WP format. In 96WP format the final volume of well was 200 μl while 
in the 384WP format it was 50 μl. In both plate formats a total of eight two-fold 
concentrations were tested. In 96WP there were three replicates of each concentration and 
in 384WP eight replicates of each concentration. In addition to the test compound wells, 
maximum growth, absorbance background and edge wells with only MHB were included 
to the plate layouts. Only MHB was added to the edge wells to prevent an edge effect.  
 
A 200-fold final concentration range stock of MEF in DMSO was prepared and stored in 
-20 ᵒC on the previous day of the assay with both plate formats. With PIP a 20-fold final 
concentration range stock was prepared on the previous day of the experiment because of 
the limited solubility of PIP in water. Other than that, protocol was the same with PIP and 
MEF in both plate formats. Test compound concentrations and concentration of the 
bacterial suspension were diluted to the final concentration in the assay with MHB. The 
tested concentration ranges of the PIP and MEF are shown in Table 1. With 96WP format, 
absorbance was measured at 0, 4, 8 and 24h time points, however the MIC was 
determined only based on the time point 24h. With 384WP format, the absorbance was 
measured only at 0 and 24h time points. Between the time points, 96WPs and 384WPs 
were incubated in plate thermo-shaker (Biosan) in conditions described above. 
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Table 1. Concentration ranges used in the antimicrobial susceptibility assays in 96-well 
plate (96WP) and 384-well plate (384WP) formats for determining MIC values of 
piperacillin (PIP) and Mefloquine (MEF). 
E. coli strain Plate format Compound Concentration range (μg/ml) 
JW5503 96WP PIP 0.5 – 0.25 – 0.125 – 0.0625 – 
0.0313 – 0.156 – 0.0078 – 
0.0039 
BAA1161 96WP PIP 2048 – 1024 – 512 – 256 – 128 
– 64 – 32 – 16 
BAA1161 96WP MEF 64 – 32 – 16 – 8 – 4 – 2 – 1 – 
0.5 
BAA1161 384WP PIP 2048 – 1024 – 512 – 256 – 128 
– 64 – 32 – 16 
BAA1161 384WP MEF 64 – 32 – 16 – 8 – 4 – 2 – 1 – 
0.5 
 
4.5 Checkerboard assays 
 
Checkerboard assays were conducted in 96WP and 384WP formats to verify the 
synergistic growth inhibition effect of PIP and MEF on E. coli BAA1161, as reported by 
Yrjänheikki (2018). In the checkerboard assay, concentration ranges of two compounds 
are combined in the assay plate and the effect of concentration combinations on growth 
inhibition is measured. A total of five checkerboard assays were conducted in 96WP and 
three were conducted in 384WP. The results of checkerboard assays were also used for 
deciding the PIP concentration to be used in the EPI screening. In all checkerboard assays 
absorbance was measured at 0, 4, 8 and 24 hour time points.    
 
In 96WP, two different checkerboard assay layouts with different PIP and MEF 
concentration ranges were studied. Different concentration ranges of PIP and MEF 
studied in checkerboard assays are presented in Table 2. Two checkerboard assays with 
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the same plate layout were conducted completely manually. Then the following three 
assays with the second layout were conducted partially automatically with Biomek i7. 
Biomek i7 was used for diluting and dispensing the PIP and MEF solutions on the 96WP. 
The same Biomek i7 protocol was used by Yrjänheikki (2018). Bacterial suspension was 
prepared and added to the wells manually in all the checkerboard assays. In the 96WP 
checkerboard assay there is only one well of each concentration combination. MEF and 
PIP source plates for the checkerboard assays were prepared on the previous day and were 
stored in -20ᵒC. Source plates for completely manually conducted 96WP checkerboard 
assays constituted of 20-fold final concentration of PIP and 100-fold final concentration 
of MEF. For the partially automated checkerboard assays 40-fold final concentration of 
PIP and 100-fold final concentration of MEF source plate was prepared. To each well of 
the 96WP checkerboard assay plate 100 μl of MHB with PIP and MEF and 100 μl of 
1x106 cfu/ml bacterial suspension was added. To the edge wells only 200 μl of MHB was 
added.        
 
In 384WP format, three checkerboard assays were conducted in different plate layouts. 
The concentration ranges of the assays are presented in the Table 2. Checkerboard assays 
were conducted in 384WP to find out whether the plate format affects the synergistic 
effect of PIP and MEF against E. coli BAA1161. 384WP checkerboard assay protocol 
followed 96WP checkerboard assay protocol with minor modifications. All checkerboard 
assays in 384WPs were conducted completely manually. Like with the 96WP, source 
plates for the 384WP checkerboard assays were prepared on the previous day to 96WP 
and were stored at -20ᵒC. PIP and MEF concentrations of the source plates were 20 and 
200-fold final concentration. However, unlike in the 96WP, each concentration 
combination had four replicates in the 384 well checkerboard assay plate, because PIP 
concentration changed every second column and MEF concentration changed every 
second row in the assay plate. An additional dilution step between the source plate and 
the assay plate called the dilution plate was included because of the lower volumes of 
384WP. The dilution plate was a 96WP were PIP and MEF concentration combinations 
were prepared and diluted to two-fold final concentration with MHB. From each well of 
the dilution plate, 25μl of PIP and MEF combination was added to four wells in the 384 
well checkerboard assay plate. Then 25μl of 1x106 cfu/ml bacterial suspension was added 
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to all of those wells, resulting in a final volume of 50μl. To the edge wells only 50 μl of 
MHB was added. 
 
Table 2. Summary of the checkerboard assays performed in the 96-well plate (96WP) and 
384-well plate (384WP) formats with combination of piperacillin (PIP) and Mefloquine 
(MEF). 
Number 
of 
replicate 
assays 
Plate 
format 
PIP concentration 
range (μg/ml) 
MEF concentration 
range (μg/ml) 
Partially 
automated 
Final 
volume of 
wells (μl) 
2 96WP 2048 – 1024 – 512 
– 256 – 128 – 64 – 
32 – 16 – 8 – 0 
64 – 32 – 16 – 8 – 
4 – 0 
No 200 
3 96WP 1024 – 512 – 256 – 
128 – 64 – 32 – 16 
– 8 – 4 – 0 
16 – 12 – 8 – 6 – 4 
– 0 
Yes 200 
1 384WP 1024 – 64 – 32 - 0 32 – 16 – 12 – 0 No 50 
1 384WP 1024 – 64 – 32 – 
16 – 0 
32 – 16 – 12 – 0 No 50 
1 384WP 256 – 0 – 256 – 0 – 
256 – 0 
16 – 12 – 8 – 6  – 0 No 50 
 
4.6 Plate uniformity assay 
 
After the checkerboard assays in 384WP, the next step in the miniaturization of the EPI 
screening method was the plate uniformity assay in 384WP. Plate uniformity assays were 
conducted according to Iversen et al (2012) with minor modifications. Plate uniformity 
assay was conducted to explore the possible effect of position in the plate on the bacterial 
growth and absorbance. By using the data of plate uniformity assay in scatter plots edge 
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and drift effects on the plate could be explored. Thus, the results of plate uniformity assay 
could be used for optimizing the plate layout for the EPI screen.    
 
The plate uniformity assay is conducted with three types of treatments which result in 
different signal levels on the plate (Iversen et al 2012). These three treatments, called 
max, mid and min, should represent different signal levels expected to be measured in the 
actual screen. The max signal wells represent maximal bacterial growth and absorbance 
expected to be measured in the actual screen. Thus, only 256 μg/ml PIP and 0.5% DMSO 
were used for the max signal treatment. For mid signal treatment 256 μg/ml of PIP in 
combination with 6 or 8 μg/ml MEF was used. The mid signal wells represent bacterial 
growth and absorbance in presence of PIP and compound with low level of antibacterial 
or synergistic activity. For the min signal the combination of 256 μg/ml of PIP and 16 
ug/ml of MEF was used as this combination was expected to completely inhibit bacterial 
growth. Thus, this min signal represents the minimal absorbance and complete inhibition 
of bacterial growth caused by the combination of PIP and compound with a strong 
antimicrobial or synergistic effect. PIP and MEF concentrations for the max, mid and min 
were determined based on the 384WP checkerboard assay results. 
 
The plate uniformity assay was conducted using the interleaved signal format (Iversen et 
al 2012). In the interleaved-signal format the plate uniformity assay consists of three 
complete 384WPs. In those three assay plates all three treatments (max, mid and min) are 
tested in all wells of the plate once (Figure 17). However, in total nine plates were 
eventually prepared because of inconsistent results of mid and max signal. Experiments 
were carried with varying conditions regarding the bacteria culture time before the assay, 
MEF concentration in the mid treatment and also with different PIP and MEF stock 
solutions to track the cause of inconsistency. Absorbance of plates was measured at the 
time points 0 and 24h with the exception of last assay plate. The absorbance of the ninth 
plate was measured at eight time points between 0 and 28 hours to determine the lag time 
of bacterial growth and difference in it between the wells. All the plate uniformity assay 
plates were prepared at different days. Treatment solutions with two-fold final 
concentrations were prepared in MHB at the day of the assay. 25μl of two-fold treatment 
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solutions and 25μl of 1x106 cfu/ml bacterial suspension was added to the wells of plate 
uniformity assay plate. 
 
Figure 17. Layouts of the plate uniformity assay interleaved-signal format 384-well assay 
plates (Iversen et al 2012). In the figure, H, M and L stand for max, mid and min 
absorbance signal levels, respectively.  
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4.7 DMSO compatibility assay  
 
As the last step before the EPI screen, the DMSO compatibility assay was performed to 
verify the DMSO tolerance of the E. coli BAA1161 in 384WP. DMSO compatibility was 
tested because the compounds to be screened are dissolved in 100% DMSO. Thus, DMSO 
compatibility dictates the highest compound concentration that can be used in the screen 
without effect of DMSO interfering the results.   
 
DMSO tolerance was tested in presence and in absence of 256 μg/ml PIP, because in the 
actual EPI screen compounds will be screened in combination with 256 μg/ml of PIP. 0; 
0.5; 1; 2; 3; 4 and 5% DMSO concentrations were tested in two independent replicate 
assays. Four replicate wells of each DMSO concentration were included in the assays. 
The assays were performed as follows: First the solutions with two-fold final DMSO and 
PIP concentrations were prepared to 96WP. From the 96WP 25μl of each solution was 
transferred to four replicate wells on the 384WP. Then 25μl of 1x106 cfu/ml bacterial 
suspension was added to the wells. Absorbance was measured at 0 and 24h time points to 
determine the effect of DMSO on bacterial growth. 
 
4.8 Test screen  
 
A library consisting of 126 natural compounds (NC) was chosen to be screened with the 
developed EPI screening assay. Compounds of the collection are presented in the 
appendix (Appendix 1). In the collection, the compounds are dissolved in DMSO at 
10mM concentration. For the screen 50 μM concentration of NCs was used in 
combination with 256 μg/ml (0.47 μM) PIP. Thus, for the screen a 200-fold dilution from 
the source plates was needed. The screen was conducted in two 384WPs with four 
replicates of each NC + PIP combination (Figure 18). In addition to the actual screening 
wells, 134 control wells were included in both 384WPs. Five types of control wells were 
included. Control wells with only 50 μl of MHB were located to the plate edges. 
Maximum bacterial growth wells with final concentrations of 0.5% DMSO and 1.3% 
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water in MHB were also included. Maximum bacterial growth wells were used for 
following the bacterial viability and for determining the effect of PIP. PIP effect controls 
with final concentrations of 256 μg/ml PIP and 0,5% DMSO in MHB were included for 
determining the antibacterial effect of PIP alone at the screening concentration. As the 
positive control a combination of 256 μg/ml PIP and 16 μg/ml MEF was used. Based on 
the checkerboard assay results, this PIP and EPI combination was expected to cause over 
90% inhibition of E. coli BAA1161 growth. MEF control with 16 μg/ml MEF and 1.3% 
water in MHB was included to quantify the effect of MEF in the positive controls. Eight 
replicate wells of each control were added to both screening plates with the exceptions of 
edge wells and PIP effect controls. In total, 32 PIP effect control wells were added to each 
plate because of the inconsistencies observed in the previous assays (i.e. plate uniformity 
and DMSO compatibility assays). 
 
The preparation of screening plates and the actual screening process are described here 
briefly. Two-fold solution with water and DMSO in MHB was prepared and stored to 
+4ᵒC on the previous day of the screen. Two-fold PIP effect control, MEF effect control 
and PIP+MEF positive control solutions were prepared on the screening day. 25 μl of 
two-fold control solutions were pipetted to the 384WPs according to the plate layout 
(Figure 18). Next, 50 μl of MHB was pipetted to the edge wells of the screening plates to 
minimize possible edge effect and as contamination controls. Then, the 200-fold dilution 
of NCs was done in two steps. First, a 100 fold dilution of NCs was done in two 96 well 
dilution plates with PIP in MHB, resulting two-fold final concentrations of NC and PIP 
in MHB. Then, 25 μl of each two-fold NC + PIP solution was pipetted from the dilution 
plate to four replicate wells in the screening 384WPs. Then, 25 μl of 1x106 cfu/ml 
bacterial suspension was added to all wells in screening 384WPs with the exception of 
edge wells. This resulted in the final volume of 50 μl in all screening plate wells. Final 
concentrations of PIP and NC in the screening wells were 256 μg/ml (0.47 μM) and 
50μM. Before the 0h absorbance measurement and incubation, the plates were 
centrifuged at 1000 rcf for 5min. Absorbance was measured at 0, 20, 24 and 28h time 
points.
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Figure 18. Layout of the 384-well screening plate used in the efflux pump inhibitor screen. EW stands for edge well, in which only Mueller-
Hinton broth (MHB) was added. MAX stands for maximum growth well, in which MHB with 0.5% of DMSO and 1.3% of water was added. 
MEFC stands for Mefloquine effect (MEF) control well, in which 16 μg/ml of MEF and 1.3% of water in MHB was added. PIPC stands for 
piperacillin (PIP) effect control well, in which 256 μg/ml of PIP and 0.5% of DMSO in MHB was added. PC stands for positive control well, 
in which 256 μg/ml of PIP and 16 μg/ml of MEF in MHB was added. SW stands for screening well, in which 50 μM of natural compound 
and 256 μg/ml of PIP in MHB was added. SWs were in four replicates with the same natural compound. All the wells had the final volume 
of 50 μl and with the exception of edge wells had the initial E. coli BAA1161 concentration of 5x105 cfu/ml. 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
A EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW
B EW MAX MAX SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW MAX MAX EW
C EW MAX MAX SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW MAX MAX EW
D EW MEFC MEFC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW MEFC MEFC EW
E EW MEFC MEFC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW MEFC MEFC EW
F EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
G EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
H EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
I EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
J EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
K EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
L EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
M EW PIPC PIPC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PIPC PIPC EW
N EW PC PC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PC PC EW
O EW PC PC SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW SW PC PC EW
P EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW EW
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4.9 Dose-response follow-up study 
 
After the EPI screen with the NCs a dose-response follow-up study was conducted with 
the NCs that showed promising activity in the screen. Growth inhibition activity of these 
NCs was determined in combination with and without 256 μg/ml of PIP to verify the 
activity seen in the screen and to measure the intrinsic antimicrobial activity of NCs. 
Thus, the results could also be used to assess whether the antimicrobial activity of these 
NCs is synergistic when combined with PIP. Tested concentration range of the NCs was 
0; 12,5; 25; 50; 75 and 100 μM. To each plate three replicate wells of each treatment were 
included and the assay was repeated once to verify the results. 
 
Briefly, the dose-response assay was performed as follows: 50-fold concentration ranges 
of the NCs were prepared in DMSO at the previous day and were stored in -20 ᵒC. On the 
day of the assay, 50μl of MHB was pipetted to the edge wells on the plate. Then, 24μl of 
MHB was added to the wells where effect of only NCs was studied. To the wells where 
the combined effect of NCs and PIP was studied, 24μl of MHB with 533.33 μg/ml PIP 
was added. Then 1μl of NCs was added from the previously prepared 50-fold 
concentration ranges. Finally, 25μl of 1x106 cfu/ml E. coli BAA1161 suspension was 
added to all but edge wells, resulting in the final volume of 50μl in all the wells.       
 
4.10 Data analysis  
 
Bacterial growth was calculated by subtracting the absorbance of the well at time point 
0h from the absorbance of the well at the time point in question. Inhibition of bacterial 
growth was calculated by dividing the bacterial growth in the well by the average bacterial 
growth of maximum growth wells and subtracting the quotient from one. Z-factors of 
antimicrobial activity assays, signal to background assay and the EPI screen were 
calculated to evaluate the quality of assays. Z-factor (Z) was calculated with the following 
formula: 𝑍 = 1 −
(3𝜎𝑚𝑎𝑥+3𝜎𝑚𝑖𝑛⁡)
|𝜇𝑚𝑎𝑥−𝜇𝑚𝑖𝑛|
 (Inglese et al 2007).  Signal to background (S:B) in the 
absorbance signal strength assessment assay was calculated with the following formula: 
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S: B =
𝜇𝑚𝑎𝑥
𝜇𝑚𝑖𝑛
  In the equations μ stands for mean absorbance and σ for standard deviation 
of absorbance. In the equations, max stands for maximum bacterial growth controls and 
min for minimum bacterial growth controls. 
 
5. RESULTS 
 
5.1 Absorbance signal strength assessment in 384-well plate format 
 
Results of the absorbance signal strength assessment in 384WP are presented in the 
Figure 19. Average absorbance of the maximum bacterial growth wells was 1.00 while 
the average absorbance of the background absorbance wells was 0.08. The value of Z-
factor was 0.88 and the signal to background was 12.77. Based on these results, it was 
concluded that absorbance measurement is a sensitive enough method for measuring the 
growth of E. coli BAA1161 in 384WP-format. Interestingly, as an indication of edge 
effect clearly lower E. coli growth was observed in the corner wells of the plate. 
 
5.2 Antimicrobial susceptibility assays 
 
MIC values determined in antimicrobial susceptibility assays in the 96WP and 384WP 
formats are presented in the Table 3. The MIC value of PIP was over 4000 times lower 
in the tolC-deleted JW5503 E. coli strain compared to the BAA1161 strain, which was 
used in the EPI screen. The MIC value of MEF was 32 μg/ml in all antimicrobial 
susceptibility assays done in both 96WP and 384WP formats. For PIP however, MIC 
values with four-fold difference were obtained in the replicate assays done in the 384WP 
format. The MIC value of PIP was also different in the 96WP format compared to the 
384WP format results. The Z-factors of the antimicrobial susceptibility assays in the 
96WP format were between 0.94 and 0.99. For the assays done in the 384WP format Z-
factors were between 0.83 and 0.89.
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Figure 19. Heat map presentation of the absorbance signal strength assessment plate. Separate color scaling was used for the two halves of 
the plate because of the drastic signal strength difference. Values presented in the figure are raw absorbance (620nm) values of the 24h 
measurement. Background absorbance wells constituted of 50 μl of Mueller-Hinton broth with 5% of water and 1% of DMSO. Maximum 
bacterial growth wells had initial bacterial concentration of 5x105 cfu/ml and constituted of 50 μl of Mueller-Hinton broth with 5% of water 
and 1% of DMSO. 
 
 
Background absorbance wells Maximum bacterial growth wells 
0.07 0.07 0.07 0.08 0.07 0.07 0.08 0.07 0.07 0.07 0.07 0.08 1.09 1.05 1.02 1.00 1.01 1.02 1.00 0.99 1.00 0.98 0.94 0.85 
0.07 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 1.08 1.06 1.02 1.01 1.01 1.03 1.02 1.03 1.04 1.04 1.04 0.93 
0.08 0.07 0.07 0.07 0.08 0.08 0.08 0.08 0.08 0.07 0.07 0.08 1.06 1.02 0.98 0.99 0.98 0.98 0.98 1.00 0.99 1.00 1.02 0.97 
0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.09 0.08 0.07 0.08 0.08 1.03 1.01 0.99 0.98 0.99 0.97 0.99 0.97 1.00 0.99 1.01 1.01 
0.08 0.08 0.07 0.08 0.08 0.08 0.09 0.08 0.08 0.08 0.07 0.08 1.03 0.99 0.97 0.98 0.98 0.97 0.96 0.99 0.98 1.00 1.01 1.01 
0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.07 0.08 1.03 1.01 0.99 0.98 0.97 0.98 0.98 0.96 0.98 0.99 1.02 1.02 
0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.07 0.08 1.04 1.00 0.97 0.98 0.98 0.97 0.98 1.01 0.99 0.97 1.01 1.03 
0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.07 0.07 0.08 1.04 1.02 1.00 0.98 0.99 0.98 0.99 0.99 0.99 1.00 1.00 1.03 
0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 1.05 1.01 0.99 0.98 1.01 0.98 0.97 0.98 0.98 0.99 1.01 1.02 
0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 1.05 1.03 1.00 1.00 0.98 1.00 0.98 0.98 0.99 1.00 1.00 1.03 
0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 1.07 0.99 0.99 0.99 0.99 0.95 0.95 1.02 0.98 1.00 0.99 1.00 
0.09 0.08 0.08 0.07 0.08 0.08 0.08 0.08 0.08 0.07 0.08 0.08 1.05 1.01 0.98 1.00 0.98 0.96 0.99 1.00 1.01 0.98 0.99 0.99 
0.08 0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.08 0.07 0.08 0.09 1.07 1.03 1.02 1.01 1.01 0.99 0.98 1.00 1.01 1.00 1.00 0.99 
0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.08 0.08 1.09 1.04 1.02 1.03 1.01 1.02 1.02 1.01 1.00 1.00 1.03 0.96 
0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.08 0.09 0.08 0.08 0.08 1.12 1.06 1.05 1.04 1.07 1.03 1.03 1.03 1.03 1.04 1.01 0.93 
0.08 0.07 0.07 0.07 0.09 0.08 0.08 0.08 0.08 0.07 0.07 0.08 1.07 1.02 1.01 1.00 0.98 0.98 0.98 0.98 0.98 0.96 0.93 0.86 
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Table 3. Determined MIC values of piperacillin (PIP) and mefloquine (MEF) in 96- 
(96WP) and 384-well plate (384WP) formats. Results are from two independent 
experiments in triplicate. With the exception of PIP’s MIC value in 384WP format, the 
same MIC values were obtained with the replicate assays. 
*Replicate assays’ results were 2048 and 512 μg/ml. 
 
5.3 Checkerboard assays  
 
Results of the three replicate checkerboard assays done in the 96WP format are presented 
in the Tables 4A and B. Results of the two other checkerboard assays done in the 96WP 
format with different MEF concentration range (two-fold) are presented in Appendix 2. 
The synergistic effect of PIP and MEF on the E. coli BAA1161 growth inhibition can be 
seen in the results of 96WP checkerboard assays. However, high variation in the growth 
inhibition level is seen with the concentration combinations which are in MIC value 
threshold. High variation in the growth inhibition level was observed especially with the 
following combinations: 256 μg/ml PIP + 6, 8 and 12 μg/ml MEF (Appendix 2 and 3). 
Nevertheless, constant over 90% growth inhibition was observed with the 256 μg/ml PIP 
+ 16 μg/ml MEF combination. 
 
Results of the checkerboard assay done in the 384WP format with 256 μg/ml PIP 
concentration is presented in Figure 20. Results of the two other checkerboard assays 
done in the 384WP format are presented in the appendix (Appendix 4). Compared to the 
96WP checkerboard assays growth inhibition caused by 256 μg/ml of PIP was constantly 
higher in 384WP. However, similar to the 96WP format, growth inhibition caused by 256 
μg/ml PIP + 6 and 8 μg/ml MEF was inconsistent. Variation of growth inhibition with 
Strain Plate format Compound MIC value (μg/ml) 
JW5503 96WP PIP 0.25 
BAA1161 
 
96WP PIP 1024 
96WP MEF 32 
384WP PIP 512—2048* 
384WP MEF 32 
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those concentration combinations was polarized as either over 95% inhibition or similar 
inhibition levels as with only 256 μg/ml PIP were measured with those PIP + MEF 
concentration combinations. Growth inhibition caused by 256 μg/ml PIP and 256 μg/ml 
PIP + 16 μg/ml MEF combination was considered consistent enough to move to the next 
assays. 
 
 
Table 4. Average (A) and standard deviation (B) of E. coli BAA1161 growth inhibition 
(%) measured in the three 96-well plate format replicate checkerboard assays. Results are 
from three independent experiments at time point 24h. 
 
 
Growth inhibition (%) 
A  Piperacillin (µg/ml) 
  
1024 512 256 128 64 32 16 8 4 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 0 95 41 9 6 5 3 3 4 4 0 
4 99 48 16 9 6 12 5 8 7 4 
6 98 51 25 14 7 7 8 9 7 6 
8 99 99 53 18 12 9 12 12 11 8 
12 99 98 78 77 61 41 25 26 23 22 
16 99 99 99 99 99 99 58 43 44 40 
Standard deviation of growth inhibition 
B  Piperacillin (µg/ml) 
  
1024 512 256 128 64 32 16 8 4 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 0 4.4 24.1 8.8 4.5 3.4 1.0 1.1 1.9 1.7 0.0 
4 0.9 24.2 8.3 4.2 3.4 9.4 2.5 3.6 3.1 2.4 
6 1.0 22.7 6.8 5.5 1.1 2.3 2.1 2.7 2.4 2.7 
8 0.7 0.7 33.8 7.3 3.0 1.8 2.3 3.6 5.2 3.7 
12 0.3 0.2 28.8 31.0 26.3 18.0 5.9 2.7 5.8 4.2 
16 0.6 0.5 0.4 0.3 0.2 0.4 28.7 1.9 4.1 4.9 
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Figure 20. E. coli BAA1161 growth inhibition (%) results at time point 24h of the 
checkerboard assay conducted in the 384-well plate format. 
 
5.4 Plate uniformity assay  
 
In the plate uniformity assay, inconsistent bacterial growth was measured in mid or in 
mid and max treatment wells of all the plates with the exception of one plate (Appendix 
5, Figure 1). As an example of observed inconsistency, results of one plate uniformity 
assay plate are presented in the Figure 21. Results of the other plate uniformity assay 
plates are presented in Appendix 5. Inconsistent and drastic variation between complete 
inhibition of growth and similar growth level as observed in the max wells was observed 
in the mid wells. However, this was basically expected as similar phenomenon was 
already observed in the checkerboard assays. Surprisingly, complete inhibition of 
bacterial growth was observed also in few max growth wells. This randomly occurring 
over 90% growth inhibition caused by 256 μg/ml PIP had not been encountered in the 
previous assays. It was observed with varying frequency in seven of the nine plate 
uniformity assay plates. Change in the bacterial culture time before the assay, in MEF 
concentration of the mid treatment and new compound stock solutions did not eliminate 
the inconsistency regarding the bacterial growth in the mid and max treatment wells. In 
  Piperacillin (µg/ml)     
  
0 0 256 256 0 0 256 256 0 0 256 256 0 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 
0 0 0 38 45 -1 -1 44 35 -2 -1 30 30 0 0 
0 1 -1 57 43 1 1 53 41 3 0 42 41 1 -1 
6 8 8 99 45 9 9 100 42 10 8 32 100 8 8 
6 9 8 100 49 12 11 96 100 11 12 100 44 9 8 
8 16 18 100 100 16 18 100 51 17 15 100 100 16 18 
8 12 11 100 48 15 13 100 49 16 13 100 100 12 11 
12 12 11 100 100 12 13 100 100 13 10 100 100 12 11 
12 11 15 100 100 15 18 100 100 13 18 100 100 11 15 
16 34 28 100 100 14 12 100 100 17 22 100 100 34 28 
16 22 10 100 100 13 11 100 100 12 13 100 100 22 10 
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the last plate uniformity assay plate it was observed that lag time of bacterial growth 
varied substantially between the wells of same treatment (Appendix 5, Figures 8a-8e).  
 
Unlike the mid and max treatment wells, the results of min treatment wells were 
consistent throughout the nine plate uniformity assay plates. Thus, it was decided that 
screening assay development would be continued, as the observed inconsistency in the 
mid and max treatment wells indicates only increased risk of false positive hits in the 
screen. However, because of these inconsistencies it was decided that only a small 
collection of NCs would be screened with four replicate wells to test the developed 
screening method. Unfortunately, results of the plate uniformity assay could not be used 
for their original purpose of optimizing the screening plate layout because of the 
inconsistencies in results. 
 
5.5 DMSO compatibility assay     
 
The growth inhibition effect of DMSO on E. coli BAA1161 in absence of PIP is shown 
in the Figure 22. DMSO concentrations up to 3% had no inhibitory effect on growth of 
E. coli BAA1161. Thus, it was decided that the screen could be conducted with up to 3% 
DMSO concentration. Results regarding the growth inhibition effect of DMSO in 
presence of PIP could not be used because of the inconsistencies in results. Similar to the 
plate uniformity assay, over 90% inhibition of growth was observed in some random 
wells with 256 μg/ml PIP. Results of the two independent DMSO compatibility assays 
are presented in Appendix 6. 
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Figure 21. Heat map presentation of the bacterial (E. coli BAA1161) growth in the sixth plate uniformity assay plate at 24h measurement. 
The treatment of each column is presented above it in the figure. The treatments were: MAX: 256 μg/ml piperacillin, MID: 256 μg/ml 
piperacillin + 6 μg/ml mefloquine, MIN: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 
5x105 cfu/ml. Inconsistency of mid and max treatment wells is well represented in this plate. There are four max treatment wells without 
bacterial growth and growth in the mid treatment wells is varying between zero and max level growth. 
 
MID MIN MAX MID MIN MAX MID MIN MAX MID MIN MAX MID MIN MAX MID MIN MAX MID MIN MAX MID MIN MAX 
-0.01 -0.01 0.84 0.73 0.00 0.80 0.38 -0.01 0.81 0.00 0.00 0.78 0.00 0.00 0.85 0.00 0.00 0.78 0.78 0.00 0.00 0.49 0.00 0.85 
0.00 0.00 0.77 0.00 0.00 0.78 0.76 0.00 0.73 0.74 0.00 0.76 0.71 0.00 0.73 0.00 0.00 0.64 0.00 0.00 0.74 0.00 0.00 0.82 
0.66 0.00 0.00 0.00 0.00 0.62 0.09 0.00 0.69 0.00 0.00 0.70 0.00 0.00 0.00 0.59 0.00 0.75 0.44 0.00 0.30 0.67 0.00 0.80 
0.00 0.00 0.66 0.72 0.00 0.76 0.72 0.00 0.63 0.57 0.00 0.67 0.00 0.00 0.79 0.42 0.00 0.73 0.62 0.00 0.74 0.78 0.00 0.80 
0.00 0.00 0.00 0.52 0.00 0.77 0.65 0.00 0.71 0.69 0.00 0.71 0.72 0.00 0.82 0.73 0.00 0.65 0.51 0.00 0.80 0.75 0.00 0.79 
0.71 0.00 0.72 0.00 0.00 0.70 0.68 0.00 0.71 0.00 0.00 0.75 0.00 0.00 0.76 0.00 0.00 0.76 0.68 0.00 0.74 0.00 0.00 0.85 
0.73 0.00 0.71 0.00 0.00 0.55 0.67 0.00 0.73 0.00 0.00 0.76 0.70 0.00 0.69 0.64 0.00 0.80 0.00 0.00 0.62 0.00 0.00 0.74 
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Figure 22. Average bacterial growth inhibition effect (± standard deviation) of the seven 
DMSO concentrations. Data was obtained from two individual assays with four replicates 
of each treatment in both. 
 
5.6 Efflux pump inhibitor screen  
 
The growth inhibition levels of NCs, presented in this section, were derived by 
subtracting the growth inhibition effect of PIP from the growth inhibition caused by NC 
+ PIP combination, based on the PIP effect controls. Complete growth inhibition results 
of both screening plates at time point 24h are presented in Appendix 7. Of the 126 
screened NCs four were found to have promising growth inhibition effect and were 
considered as hits. Properties and screening results of those four NCs are presented in the 
Table 5. Molecular structures of the four hit compounds are presented in Figures 23-26. 
Three of the four hit compounds had relatively consistent growth inhibition effect in all 
four replicate wells. However, the growth inhibition percentages of one hit compound, 
Isopropyl gallate (IG), were varying between -1.6 and 100% in the replicate wells, 
indicating possibility of false positive hit, resulting from the inconsistent growth 
inhibition caused by 256 μg/ml PIP. In the two screening plates total of seven wells (1.4% 
of the screening wells) with growth inhibition percentages between 75 and 100% were 
considered to be caused by the inconsistent effect of 256 μg/ml PIP. That conclusion was 
made based on the fact that in those seven wells multiple times higher growth inhibition 
was measured in one well compared to the three other replicate wells. Occurrence of 
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random extremely high growth inhibition values was expected because the same 
phenomenon was encountered in the plate uniformity and DMSO compatibility assays 
with PIP. Z-factors of the screening plates were 0.95 at the 24h time point. 
 
Table 5. Summary of the screening results and properties of the four hit natural 
compounds found with the screen.  
Code Name Inhibition 
(%)* 
Standard 
deviation 
Molecular 
weight 
(g/mol) 
Concentration 
(μg/ml) 
NC43 (-)-Epigallocatechin 
gallate 33 1.5 458.37 22.92 
NC54 Hamamelitannin 30 5.8 484.37 24.20 
NC66 Isopropyl gallate 52 37.5 212.21 10.61 
NC84 Octyl gallate 45 4.2 282.34 14.12 
*Growth inhibition effect of natural compound was calculated by subtracting 
piperacillin’s effect from the growth inhibition effect of piperacillin + natural compound 
combination, based on the piperacillin effect controls of the screen. 
Figure 23. Molecular structure of the epigallocatechin gallate (Merck KGaA 2019b). 
Figure 24. Molecular structure of hamamelitannin (Merck KGaA 2019c). 
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Figure 25. Molecular structure of isopropyl gallate (Narwal et al 2012). 
Figure 26. Molecular structure of octyl gallate (Merck KGaA 2019d) 
 
5.7 Dose-response assay  
 
Two of the four hit compounds, Hamamelitannin (HT) and Octyl gallate (OG) had 
promising results also in the first dose-response assay. Results of the first dose-response 
assay are presented in the Figure 27. When 100μM of HT was combined with 256 μg/ml 
PIP it resulted on average 94% growth inhibition. Separately the same concentrations of 
PIP and HT resulted growth inhibition levels of only 44% and 9%. OG caused an average 
growth inhibition of 100% with 75μM concentration when combined with 256 μg/ml PIP, 
but the growth inhibition caused by the 75μM OG alone was only 15%. Thus, these results 
indicate synergistic E. coli BAA1161 growth inhibition effect for HT and OG when 
combined with PIP.  
 
Unfortunately, the results of the second dose-response assay could not be used for 
evaluating the effect of NCs when combined with PIP because of the similar 
inconsistencies as encountered in the plate uniformity assay, DMSO compatibility assay 
and in the EPI screen (Appendix 8). Random over 97% growth inhibition was measured 
only in the wells were effect of NC was studied in combination with 256 μg/ml PIP. 
Results of the wells with only NC were similar to the first assay’s results. Based on these 
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assays, the four hit NCs possess only poor intrinsic antibacterial activities. The MIC 
values of Epigallocatechin gallate (EGCG), HT, IG and OG are all over 100μM. In fact, 
the highest measured intrinsic growth inhibition level of these NCs was 20% with 100μM 
concentration of OG. 
 
Figure 27. Average bacterial growth inhibition effect (± standard variation) of the natural 
compounds in combination with and without 256 μg/ml piperacillin (PIP). Experiment 
was performed once in triplicates. Natural compounds included in the experiment are 
Epigallocatechin gallate (EGCG), Hamamelitannin (HT), Isopropyl gallate (IG) and 
Octyl gallate (OG). Synergistic nature of HT’s (100μM) and OG’s (75μM) bacterial 
growth inhibition effect is observed when combined with piperacillin.   
 
6. DISCUSSION 
 
The experimental part of this thesis was a continuation of the EPI screening method 
development started by Yrjänheikki (2018) in her M. Sc. thesis. E. coli strain (BAA1161), 
antibiotic (piperacillin) and the positive control EPI (mefloquine) for the EPI screening 
assay were chosen based on her results. The E. coli strain BAA1161 was chosen based 
on H33342 accumulation assay results and its role as a clinically relevant uropathogenic 
strain. In the H33342 accumulation assay, median intracellular accumulation of H33342 
0
10
20
30
40
50
60
70
80
90
100
PIP EGCG 
(100μM)
EGCG 
(100μM)   
+ PIP
HT 
(100μM)
HT 
(100μM)     
+ PIP
IG 
(100μM)
IG 
(100μM)     
+ PIP
OG 
(75μM)
OG 
(75μM)       
+ PIP
G
ro
w
th
 in
h
ib
it
io
n
 (
%
)
Growth inhibition caused by NCs in combination with and 
without piperacillin
58 
 
was most increased in BAA1161 of the tested E. coli strains with all the EPIs tested, when 
the accumulation was compared to results without EPI. Thus, the results of H33342 
accumulation assay suggest that E. coli strain BAA1161 has high efflux pump activity 
which can be suppressed with EPIs. PIP was chosen as the antibiotic for the screen as of 
the four tested antibiotics its MIC value decreased the most in the tolC deleted strain 
(JW5503) when compared to its parental strain (BW25113). PIP’s MIC value for the 
BAA1161 strain was also above CLSI’s MIC-breakpoint for resistance, which is 128 
μg/ml, and in the checkerboard assay EPI MEF caused a two-fold reduction in PIP’s MIC 
value with a sub-inhibitory concentration (CLSI 2018, Yrjänheikki 2018). All in all, 
results of Yrjänheikki (2018) indicate that efflux pumps play a substantial role in PIP 
resistance of BAA1161 making it good antibiotic for the EPI screening assay. MEF was 
chosen as the positive control EPI for the screen also based on the H33342 accumulation 
assay results (Yrjänheikki, 2018). MEF caused the highest median intracellular H33342 
accumulation of the tested EPIs in all of the tested E. coli strains with the exception of 
JW5503.  
 
Determined MIC values of MEF and PIP and the results of the checkerboard assays were 
mostly in line with the results of Yrjänheikki (2018), as expected. The determined MIC 
value of MEF was the same in both plate formats and the same as was determined by 
Yrjänheikki. In 96WP format, MIC value of PIP differed two-fold when compared to 
Yrjänheikki’s results which, however, is still considered acceptable level of 
reproducibility by CLSI (Yrjänheikki, 2018; CLSI, 2012). The synergistic effect of PIP 
and MEF observed in the 96WP checkerboard assays was also relatively similar to results 
of Yrjänheikki (2018). Similarity in the results of these repeated assays verifies the 
determined susceptibility and synergy levels. It is important as the later stages of EPI 
screening method development are based on those results. Reproducibility by different 
persons is also important for the reliability of the method.   
 
Based on the results of antimicrobial susceptibility and checkerboard assays, a PIP 
concentration of 256 μg/ml was chosen to be used in the screen in combination with the 
screen NCs. This concentration was also recommended by Yrjänheikki (2018) in her 
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thesis. 256 μg/ml was the highest PIP concentration which never caused MIC-level of 
growth inhibition in experiments done in 96WP format or in the experiments conducted 
by Yrjänheikki (2018). In the checkerboard assays, a MEF concentration two-fold lower 
than the MIC consistently caused a growth inhibition level of over 90% when combined 
with 256 μg/ml PIP. Thus, 256 μg/ml was considered as a PIP concentration which with 
also less potent EPIs could be detected without false positives.  
 
However, persistent inconsistencies were later encountered with 256 μg/ml PIP. 
Inconsistency in bacterial growth inhibition effect of 256 μg/ml PIP was observed in all 
the assays conducted in 384WP format. In 384WP checkerboard assay the highly 
polarized variation in the growth inhibition was encountered for the first time. Only less 
than 51% and over 95% growth inhibition values were measured with 256 μg/ml PIP + 6 
and 8 μg/ml MEF combinations. This polarized variation in the growth inhibition was 
then observed in all the following assays where growth inhibition effect of PIP was 
measured in 384WP format. 
 
These inconsistent results with 256 μg/ml PIP could be resulting from hetero resistance 
of E. coli BAA1161 strain against PIP. Antimicrobial hetero resistance has been defined 
as a “phenomenon where subpopulations of seemingly isogenic bacteria exhibit a range 
of susceptibilities to a particular antibiotic” (El-Halfawy and Valvano 2015). Mechanisms 
causing the hetero resistance can be genetic, epigenetic and even non-genetic. Hetero 
resistance seems to usually result in bacterial subpopulations that can grow in antibiotic 
concentrations substantially above MIC. However, in this case the situation seemed to be 
the opposite as the sub-MIC PIP concentration was causing inconsistent over 90% 
bacterial growth inhibition in some wells. Nevertheless, a similar phenomenon has also 
been encountered when polymyxin B susceptibility of clinical E. cloacae and E. 
aerogenes isolates was studied (Landman et al 2013). In antimicrobial susceptibility 
assays some of the E. clocae and E. aerogenes isolates showed no visible growth in 
multiple wells with polymyxin B concentration lower than in wells where growth 
inhibition was not observed.  E. clocae and E. aerogenes isolates contained 
subpopulations which were causing antibiotic hetero resistance.  
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But why the inconsistencies in growth inhibition effect of PIP were observed only in the 
384WP format? This might be just because of the lower number of replicate wells in 
96WP and lower number of assays conducted with 96WP format. However, as 
Yrjänheikki (2018) did not encounter similar inconsistencies in her experiments, which 
were all conducted in 96WP format, it seems more likely that inconsistencies are related 
to the 384WP format. Reason could be the size of bacterial inoculum. The same bacterial 
concentration was used in the experiments conducted in the 96WP and 384WP formats. 
Thus, the initial amount of bacterial cells in the wells was a four-fold lower in 384WP 
format compared to 96WP format. Possibly, in some wells of 384WP this smaller 
bacterial population did not survive the lag phase before start of bacterial growth in 
presence of 256 μg/ml. Substantial differences in the duration of lag phase were observed 
in wells with 256 μg/ml PIP in the plate uniformity assay (Appendix 5, Figures 8a-8e). 
The second theory is, that the used E. coli BAA1161 strain has a small subpopulation 
which is able to grow in presence of 256 μg/ml PIP while the main population is more 
susceptible to PIP. Then, when a four-fold lower initial amount of bacteria is used in 
higher number of replicate wells in 384WP format the probability of not adding bacteria 
belonging to the subpopulation to some of the wells is increased. These wells would then 
be seen as random wells without bacterial growth. The possibility of subpopulations could 
be studied by growing of BAA1161 cells on agar plates with 256 μg/ml PIP. 
  
The latest experiments performed in the laboratory also support the hypothesis that the 
lower initial amount of bacteria in the wells is related to the inconsistent growth inhibition 
effect of PIP in the 384WP format (data not shown). No random over 90% growth 
inhibition values were measured when the effect of 256 μg/ml PIP on growth of E. coli 
BAA1161 was studied in 384WP format with the initial bacterial concentration of 2x106 
cfu/ml. However, when the same initial bacterial concentration (5x105 cfu/ml) was used 
as in the 96WP format similar inconsistencies in the bacterial growth inhibition were 
observed as in the plate uniformity assay, DMSO compatibility assay, dose-response 
assay and EPI screen of this thesis.                    
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The screening method was miniaturized to 384WP format despite the additional work that 
the miniaturization process causes, because of the multiple benefits of the 384WP format. 
Compared to a similar assay in 96WP format lower volumes of reagents can be used in 
the 384WP format. Also more compounds can be screened in one plate with the 
miniaturized assay. Thus, the miniaturization of an assay can result in lower reagent costs, 
increased throughput and decreased requirement for plate incubation space. However, in 
this case optimization of bacterial inoculum size should have been included in the 
miniaturization process of the screening assay. Inoculum size optimization was neglected 
as CLSI’s standard concentration of 5x105 cfu/ml has been used in similar previously 
conducted assays. For instance, Chase et al (2016) used 5x105 cfu/ml concentration of E. 
cloacae and Acinetobacter species in antimicrobial synergy assay in 384WP format with 
the final volume of 60μl. Also Miyasaki et al. (2013) used 5x105 cfu/ml concentration of 
E. coli in 384WP format with the final volume of 40 μl per well, when determining the 
growth inhibition effect of combined antimicrobial compounds. On the other hand, the 
difficulties in 384WP format resulting from the inconsistent growth of BAA1161 in 
presence of PIP, could possibly have been avoided if completely different strategy for 
screening method development had been chosen. If the EPI screening method had been 
developed directly into 384WP format, instead of miniaturization, possibly the 
inconsistency in growth inhibition effect of PIP on BAA1161 would have been 
encountered earlier. As a result, an antibiotic and an E. coli strain which would have been 
more suitable for this method in 384WP format could have been chosen.        
 
Despite the above mentioned difficulties, objectives of developing an EPI screening 
method and using the developed method for a test screen were reached. Inconsistent and 
random over 90% growth inhibition values, likely caused by PIP, were observed in the 
screen. However, the frequency of this phenomenon was low enough that with four 
replicate wells it did not lead to difficulties in interpreting the screening results. Still, the 
mechanism behind the inconsistent growth inhibition caused by PIP in 384WP should be 
explored and the effect of higher initial bacterial concentration on the reproducibility of 
the assay should be studied in the future experiments. If the higher inoculum size does 
not prevent the inconsistencies, change of the antibiotic or bacterial strain should be 
considered.  
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Hit compounds leading to development of EPIs D13-9001 and NMP were found by using 
a screening strategy similar to ours (Nakayama et al. 2003a; Bohnert and Kern 2005). 
Similarly, compound collections were screened in combination with antibiotic against an 
efflux pump overexpressing bacterial strain. However, also different screening methods 
have been developed to find novel EPIs against bacterial efflux pumps. Haynes et al 
(2018) have developed a fluorochrome retention based high-throughput flow cytometry 
EPI screening assay. In this method, intracellular retention of diacetyl fluorescein is 
measured in presence of screen compounds. Diacetyl fluorescein is a fluorescent RND 
efflux pump substrate whose intracellular retention time is increased by EPIs. With this 
method the known EPIs PAβN and NMP were found active, supporting the reliability of 
the method. In silico methods have also been used for screening EPIs against bacterial 
efflux pumps. For instance, Verma and Tiwari (2018) conducted a multiple step virtual 
high through put screen to find novel inhibitors of AdeC.  AdeC is the outer membrane 
protein of AdeABC RND transporter complex of A.  baumannii. Before the screen a 3D 
model of AdeC was prepared. The in silico screen was comprised of ADMET filter 
(absorbance, distribution, metabolism, excretion and toxicity), three docking assays of 
increasing precision and MD-simulation. This method was used to find the most 
promising AdeC inhibitor of 2 737 560 compounds included in the screen. 
 
All the four NCs which showed promising growth inhibition in the test EPI screen were 
gallic acid esters. Three of those were gallates: epigallocatechin gallate (EGCG) (Figure 
23), isopropyl gallate (IG) (Figure 25) and octyl gallate (OG) (Figure 26). In addition to 
these three gallates, there was one more gallate, called epicatechin gallate, included in the 
screened NC collection. Surprisingly, epicatechin gallate showed substantially lower 
growth inhibition activity in the test screen (average growth inhibition of 17% at 24h) 
and, thus, was not considered as hit. The fourth NC that showed promising EPI activity 
in the screen was hamamelitannin (HT) (Figure 24). HT is a tannin with two gallic acid 
esters in its molecular structure. Because of the gallic acids, all the four NCs that showed 
promising bacterial growth inhibition activity in the test screen possess multiple phenol 
groups in their structure. Multiple hydrophobic ring systems in the molecular structure is 
63 
 
typical for known bacterial RND EPIs. The four promising NCs have multiple aromatic 
ring systems or a ring system and an alkyl chain in their structure but the hydrophobicity 
of these aromatic ring systems is reduced because of the multiple phenol groups. Of these 
four NCs HT and OG showed especially interesting activity in follow-up dose-response 
assay. Growth inhibition effect of HT and OG with 256 μg/ml PIP was substantially 
greater than the combined growth inhibition caused by these NCs and 256 μg/ml PIP 
separately, suggesting synergistic effect. 
 
Based on the literature, EGCG is the most studied of the four NCs, which showed 
promising activity in the test EPI screen. EGCG is the most abundant of the four main 
catechins in green tea (Reygaert 2014). Green tea catechins have been shown to have 
synergistic and intrinsic antibacterial activity, based on cell wall damaging and fatty acid 
synthesis inhibiting mechanisms. In E. coli EGCG’s MIC value is 400 μg/ml, based on a 
study conducted with ten E. coli strains (Jeon et al 2014). The E. coli strains of the study 
included clinical multi drug resistant isolates. Results of Kanagaratnam et al (2017) show 
that RND efflux pumps play a role in EGCG’s antibacterial mechanism of action in P. 
aeruginosa. Impairment of MexAB-OprM efflux pump complex enhanced the synergistic 
antimicrobial effect of EGCG with chloramphenicol and tetracyclines. Also, the 
combination of EGCG with the EPI PAβN resulted in synergistic antibiotic potentiating 
effect in wild type P. aeruginosa. In Campylobecter species EGCG increased 
susceptibility to macrolides with sub-MIC concentration (Kurincic et al 2012). Macrolide 
potentiating effect of EGCG had correlation with the effects of EPIs PABN and NMP, 
included in the study. All in all, the antibiotic potentiating effect of EGCG, observed in 
the EPI screen, has been detected in multiple bacterial species with multiple types of 
antibiotics. It is also recognized, that RND efflux pumps affect the antibiotic potentiating 
effect of EGCG. 
 
HT is found from bark and leaves of the tree Hamamelis virginiana (Kiran et al 2008). 
Based on the literature, research regarding the antibacterial activity of HT has mainly 
been focused on its effects against Staphylococcus aureus. HT affects biofilm formation 
of S. aureus by affecting its quorum sensing (Kiran et al 2008; Brackman et al 2016). In 
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vitro HT decreases S. aureus biofilm formation and increases the susceptibility of 
biofilms to multiple classes of antibiotics (Cobrado et al 2012; Brackman et al 2016). It 
has also been shown that HT prevents biofilm formation on surface of medical devices in 
vivo (Kiran et al 2008; Cobrado et al 2013; Brackman et al 2016). Biofilm formation 
reducing activity of HT has also been shown with GNB A. baumannii in vitro (Cobrado 
et al 2012). No research was found regarding HT’s antimicrobial activity against E. coli 
or regarding effux pump inhibition. The results presented in literature, however, suggest 
that a very high concentration of HT is required to reach the MIC in Gram-negative and 
positive bacterial species (Kiran et al 2008; Cobrado et al 2012). It is possible, that the 
activity of HT determined in our experiments is related to the anti-biofilm effect, as the 
384WPs were incubated without agitation in our experiments. All in all, similar results 
regarding the observed HT’s E. coli growth inhibition effect in combination with 
antibiotic, were not found from the literature. 
 
No articles were found regarding the antibacterial activity of IG. In the test EPI screen it 
had the highest average growth inhibition effect of the screened NCs. There was, 
however, a very high variation in the measured growth inhibition levels of the replicate 
wells with IG. Bacterial growth inhibition levels of the replicate wells were between 100 
and -1.6% (Appendix 7, Figure 1). On the other hand, in the dose-response study the 
growth inhibition effect of IG was relatively constant but lower than HT’s and OG’s. 
Thus, it seems likely that the high growth inhibition effect of IG observed in the EPI 
screen was resulting partially from the inconsistent growth inhibition effect of PIP. 
 
In the dose-response assay, OG showed highest bacterial growth inhibition activity of the 
four NCs, when combined with PIP. It caused an average growth inhibition of 100% at 
75μM concentration when combined with 256 μg/ml PIP, while the growth inhibition 
levels of OG and PIP separately were only 15 and 44%, indicating synergism. OG is used 
in food industry as an antioxidant (Rua et al 2011). Based on the results of Kubo et al 
(2003), it has a low antimicrobial activity against GNB species of E. coli, P. aeruginosa 
and E. aerogenes with MIC values of over 800 μg/ml (2.8 mM). On the other hand, it has 
substantially lower MIC values, ranging from 12.5 to 50 μg/ml (44 to 177 μM), against 
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GNB species of Proteus vulgaris and Salmonella choleraesuis and against all Gram-
positive bacterial species and fungi that were included in the study. Possibilities of using 
OG against Helicobacter pylori infections have also been studied in vitro because of its 
antioxidant and antimicrobial properties (Wolf et al 2017). MIC value of 125 μg/ml (443 
μM) was determined for OG against H. pylori. Alkyl gallates included in the study 
showed increasing bacterial growth inhibition with increasing alkyl chain length, 
suggesting cell membrane destabilization related mechanism. The antifungal mechanism 
of OG is also likely resulting from membrane destabilization (Kubo et al 2001). All in 
all, no results regarding a synergistic antibacterial activity of OG with antibiotics were 
found from the literature. Low intrinsic antimicrobial effect of OG against E. coli 
observed in the dose-response assay is in line with the previous studies. Based on the 
literature, it seems also possible that the observed synergistic antibacterial effect of OG 
with PIP, is resulting from increased membrane permeability. 
 
Synergistic antibacterial effect of HT and OG with PIP against E. coli BAA1161 should 
be verified in the future experiments. It should also be studied whether the synergism is 
resulting from efflux pump inhibition or from other mechanisms, like outer membrane 
permeabilization. Synergistic effect of these NCs with PIP could be verified in 
checkerboard assays. The role of efflux pumps for the synergism could also be studied in 
the checkerboard assays by using both efflux pumps overexpressing E. coli strains and E. 
coli strains with impaired or deleted efflux pumps. Also H33342 accumulation assay 
could be used for studying the EPI activity of these NCs (Coldham et al 2010). 
 
7. CONCLUSIONS 
 
Bacterial antibiotic resistance is a global and progressive health threat. It is diminishing 
the effectivity of antibiotics by multiple mechanisms. One of these resistance mechanisms 
is mediated by bacterial efflux pumps which reduce the intracellular antibiotic 
concentration. Bacteria express multiple types of efflux pumps but the RND family of 
efflux pumps is especially important for the antibiotic resistance. In this thesis, an assay 
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for screening novel inhibitors against RND efflux pumps of E. coli was developed and 
tested with a small collection of natural compounds. 
 
During the development of the EPI screening method, unexpected difficulties were 
encountered regarding the inconsistent growth inhibition effect of PIP against E. coli 
strain BAA1161 in 384WP format. These inconsistencies suggest that the strain may 
contain subpopulations which cause the encountered hetero resistance phenomenon. 
These results should be taken into consideration in future experiments with the E. coli 
strain BAA1161. It should also be carefully considered which factors should be optimized 
in the miniaturization process of an assay. For instance, it was apparently a mistake that 
the initial bacterial concentration was not optimized during the miniaturization process of 
this assay. Developing the assay directly to 384WP format instead of having a 
miniaturization process from 96WP to 384WP format could also help to avoid these kind 
of difficulties.     
 
Despite the difficulties caused by the inconsistencies a test EPI screen was successfully 
conducted. Based on the screen, the developed method can be used in the future to find 
novel EPIs against E. coli. However, it would be beneficial to solve the issues regarding 
the inconsistent growth inhibition effect of PIP to increase the reliability of the method.  
 
NCs with novel synergistic antimicrobial activity were found with the test screen of the 
developed method. All the compounds that showed promising activity in the screen 
contained gallic acid ester, indicating that gallates and other gallic acid esters may possess 
interesting antibiotic potentiating properties. Potential of gallic acid esters as antibiotic 
adjuvants should be determined in the future experiments. In the follow-up assay of the 
test EPI screen, two gallic acid esters showed synergistic antibacterial activity with PIP. 
Although the developed screening method is optimized to find compounds with EPI 
activity, the PIP potentiating activity of these NCs could also be resulting from outer 
membrane permeabilization, for instance. After all, it has to be remembered that relatively 
high concentrations of these gallic acid esters were required for the synergistic effects. 
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Gallic acid esters may, however, possess a scaffold that could be optimized towards more 
potent antibiotic adjuvants in the future. 
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 APPENDIX 1: Natural compounds collection used in the test screen.   
 
Table 1. Properties of the natural compounds screened in the efflux pump inhibitor 
screen at 50 μM concentration in combination with 256 μg/ml of piperacillin against E. 
coli BAA1161. 
Number of 
compound Name of the compound 
Molecular weight of 
the compound 
(g/mol) Supplier of the compound  
NC001 Arbutin 272.3 Sigma 
NC002 Alpha-naphthoflavone 272.9 Acros 
NC003 Apigenin 270.24 Fluka 
NC004 Artemisinin 282.35 Extrasynthese 
NC005 L-Ascorbic acid 176.1 Sigma 
NC006 Baicalein 270.25 Extrasynthese 
NC007 Baicalin 446.36 Extrasynthese 
NC008 Benzoic acid 122.12 BDH Chemicals Ltd. 
NC009 3-Benzoylbenzo(F)coumarin 300.30 Acros 
NC010 3-(2-Benzoxazolyl)umbelliferone 279.25 Fluka 
NC011 Boldine hydrochloride 363.84 Extrasynthese 
NC012 Butylhydroxyanisole 180.2 Sigma 
NC013 Butylhydroxytoluene 220.4 Sigma 
NC014 Caffeic acid 180.16 Extrasynthese 
NC015 (+)-Catechin 290.3 Sigma 
NC016 (+/-)-Catechin 290.3 Sigma 
NC017 Catechol 110.1 Sigma 
NC018 Chrysin 254.25 Extrasynthese 
NC019 o-Coumaric acid 164.2 Sigma 
NC020 m-Coumaric acid 164.16 Fluka 
NC021 4-Coumaric acid 164.16 Extrasynthese 
NC022 Coumarin 102 255.32 Acros 
NC023 Coumarin 30 347.42 ICN 
NC024 Coumarin 7 333.38 Acros 
NC025 Coumarin 146.15 Merck 
NC026 Daidzein 254.25 Extrasynthese 
NC027 Daidzin 416.38 Extrasynthese 
NC028 Daphnetin 178.15 Extrasynthese 
NC029 7-Diethylamino-3-thenoylcoumarin 327.39 Acros 
NC030 2,3-Dihydroxybenzoic acid 154.12 Fluka 
NC031 2,4-Dihydroxybenzoic acid 154.12 Fluka 
NC032 2,5-Dihydroxybenzoic acid 154.12 Fluka 
NC033 2,6-Dihydroxybenzoic acid 154.12 Fluka 
NC034 3,4-Dihydroxybenzoic acid 154.12 Fluka 
NC035 3,5-Dihydroxybenzoic acid 154.12 Fluka 
NC036 2,5-Dimethyl-phenol 122.17 Fluka 
NC037 6,2-Dimethoxyflavone 282.3 ICC 
NC038 5-Dimethylaminonaphthalene-1-sulfonylchloride 269.75 Fluka 
NC039 Ellagic acid 302.2 Sigma 
NC040 (-)-Epicatechin 290.3 Sigma 
NC041 (-)-Epicatechin gallate 442.37 Extrasynthese 
NC042 (-)-Epigallocatechin  306.28 Extrasynthese 
NC043 (-)-Epigallocatechin gallate 458.37 Extrasynthese 
NC044 Esculetin 178.15 Extrasynthese 
NC045 Esculin 340.29 Extrasynthese 
NC046 Ethoxyquin 217.3 Sigma 
 NC047 Ferulic acid 194.19 Extrasynthese 
NC048 Flavone 222.25 Carl Roth GmbH 
NC049 Fraxetin 208.17 Extrasynthese 
NC050 Hesperetin 302.29 Extrasynthese 
NC051 Genistein 270.23 Extrasynthese 
NC052 Hippuric acid 179.18 APIN Chemicals Ltd. 
NC053 Gossypin 480.38 Extrasynthese 
NC054 Hamamelitannin 484.37 Extrasynthese 
NC055 Hesperidin 610.57 Sigma 
NC056 Hydroquinone 110.11 Fluka 
NC057 3-Hydroxyacetophenone 136.15 Fluka 
NC058 4-Hydroxyacetophenone 136.15 Fluka 
NC059 4-Hydroxycoumarin 162.15 Extrasynthese 
NC060 2-Hydroxyphenylacetic acid 152.15 Fluka 
NC061 3-Hydroxyphenylacetic acid 152.15 Fluka 
NC062 4-Hydroxyphenylacetic acid 152.15 Fluka 
NC063 Hypericin 504.43 Carl Roth GmbH 
NC064 Isopimpinellin 246.22 Carl Roth GmbH 
NC065 Bergapten, 5-Methoxypsoralen 216.20 Aldrich 
NC066 Isopropyl gallate 212.21 Extrasynthese 
NC067 Isorhamnetin 316.28 Extrasynthese 
NC068 Kaempferol 286.25 Extrasynthese 
NC069 Khellin 260.24 Carl Roth GmbH 
NC070 Luteolin 286.25 Extrasynthese 
NC071 Luteolin-7-glucoside 448.38 Extrasynthese 
NC072 Malvin chloride 691.01 Extrasynthese 
NC073 6-Methylcoumarin 160.17 Extrasynthese 
NC074 4-Methyldaphnetin 192.17 Extrasynthese 
NC075 4-Methyl pyrocatechol 124.14 Merck 
NC076 Methyl umbelliferone 176.17 
NC077 Morin dihydrate 338.26 Carl Roth GmbH 
NC078 Myricetin 318.25 Extrasynthese 
NC079 Myricitrin 464.38 Extrasynthese 
NC080 Naringenin 272.27 Extrasynthese 
NC081 2'-Methoxy-alpha-naphthoflavone 302.3 ICC 
NC082 Naringin 580.53 Carl Roth GmbH 
NC083 Nordihydroguaiaretic acid 302.37 Fluka 
NC084 Octyl gallate 282.34 Fluka 
NC085 Phtalic acid 166.13 Merck 
NC086 Protocatechuic acid 154.13 Extrasynthese 
NC087 Psoralen 186.17 Extrasynthese 
NC088 Pyrogallol 126.11 Riedel-de Haën 
NC089 Quercetin krist. 338.27 Merck 
NC090 Quercitrin dihydrate 484.43 Carl Roth GmbH 
NC091 (-)-Quinic acid 192.2 Sigma 
NC092 Resorcin 110.11 Riedel-de Haën 
NC093 Resveratrol 228.25 Extrasynthese 
NC094 Rhamnetin 316.28 Extrasynthese 
NC095 Rosmarinic acid 360.33 Extrasynthese 
NC096 Rotenone 394.41 Acros 
NC097 Rutin 664.58 Merck 
NC098 D(-)-Salicin 286.27 Carl Roth GmbH 
NC099 Salicylic acid 138.13 AnalaR 
NC100 Scopoletin 192.17 Extrasynthese 
NC101 Sennoside B 862.75 Oy Extracta Ltd. 
NC102 Silybin 482.43 Carl Roth GmbH 
NC103 Sinapic acid 224.22 Fluka 
 NC104 Sinigrin monohydrate 415.49 Carl Roth GmbH 
NC105 Syringic acid 198.2 Sigma 
NC106 (+)-Taxifolin 304.27 Extrasynthese 
NC107 Tectochrysin 268.28 Extrasynthese 
NC108 Thymol 150.22 Riedel-de Haën 
NC109 Thymoquinone 164.2 MP Biomedicals, Inc. 
NC110 3,4,5-Trimethoxybenzoic acid 212.2 Sigma 
NC111 
6-Hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid (Trolox) 250.29 Aldrich 
NC112 Umbelliferone 162.14 Carl Roth GmbH 
NC113 Vanillic acid 168.15 Extrasynthese 
NC114 Uric cid 168.1 Sigma 
NC115 Vanillin 152.15 Merck 
NC116 Xanthotoxin 216.19 Extrasynthese 
NC117 Gitoxigenin 390.51 Carl Roth GmbH 
NC118 Gitoxin 780.96 Merck 
NC119 Digoxin 780.96 Fluka AG 
NC120 Digitoxigenin 374.5 Sigma 
NC121 Lanatosid A 969.15 Carl Roth GmbH 
NC122 Lanatosid B 985.1 SERVA 
NC123 Lanatosid C 985.14 Carl Roth GmbH 
NC124 Chinin 324.43 Fluka AG 
NC125 Cinchonidine 294.40 BDH 
NC126 Cinchonine 294.40 BDH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 APPENDIX 2: Results of the checkerboard assays done in the 96-well plate (96WP) 
format with two-fold mefloquine and piperacillin concentration ranges. 
 
 
Figure 1. Growth inhibition (%) of the first checkerboard assay done in the 96WP 
format. In total five checkerboard assays were conducted in 96WP format and in two of 
those two-fold mefloquine concentration range was used.   
 
Figure 2. Growth inhibition (%) of the second checkerboard assay done in the 96WP 
format. In total five checkerboard assays were conducted in 96WP format and in two of 
those two-fold mefloquine concentration range was used. 
 
 
 
 
 
  Piperacillin (µg/ml) 
  
1024 512 256 128 64 32 16 8 4 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 0 99 99 32 8 3 1 2 16 3 0 
4 99 99 50 8 6 5 2 3 4 4 
8 99 99 99 21 11 9 4 5 9 3 
16 99 99 99 99 100 99 99 38 32 32 
32 99 99 99 99 99 99 99 99 100 99 
64 100 99 100 100 100 100 100 100 100 100 
  Piperacillin (µg/ml) 
  
1024 512 256 128 64 32 16 8 4 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 0 99 99 47 12 7 4 3 3 4 0 
4 99 99 57 19 6 4 5 3 6 1 
8 99 99 89 32 14 8 14 15 6 4 
16 100 99 93 99 99 99 99 51 34 33 
32 100 99 99 100 100 100 100 99 99 100 
64 100 100 100 100 99 100 100 100 100 100 
 APPENDIX 3: Results of the checkerboard assays done in the 96-well plate (96WP) 
format with non-geometric mefloquine concentration range.  
 
 
Figure 1. Growth inhibition (%) of the first checkerboard assay done in the 96WP 
format with non-geometric mefloquine concentration range. In total five checkerboard 
assays were conducted in 96WP format and in three of those non-geometric mefloquine 
concentration range was used. 
 
 
Figure 2. Growth inhibition (%) of the second checkerboard assay done in the 96WP 
format with non-geometric mefloquine concentration range. In total five checkerboard 
assays were conducted in 96WP format and in three of those non-geometric mefloquine 
concentration range was used. 
  Piperacillin (µg/ml) 
  
1024 512 256 128 64 32 16 8 4 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 0 99 28 1 2 4 4 1 2 3 0 
4 99 31 8 6 2 4 2 3 3 1 
6 99 33 28 7 7 4 5 5 4 2 
8 99 99 99 13 9 7 11 7 4 3 
12 99 99 37 33 39 20 17 24 15 16 
16 99 99 99 98 99 99 37 45 39 35 
  Piperacillin (µg/ml) 
  
1024 512 256 128 64 32 16 8 4 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 0 89 21 5 4 1 2 3 3 2 0 
4 100 30 13 6 7 26 5 11 8 7 
6 99 37 16 15 7 9 8 10 9 6 
8 100 100 18 12 12 7 16 15 16 11 
12 99 98 99 100 47 38 30 25 25 25 
16 100 100 99 99 99 99 38 43 43 40 
  
 
 
 
Figure 3. Growth inhibition (%) of the third checkerboard assay done in the 96WP 
format with non-geometric mefloquine concentration range. In total five checkerboard 
assays were conducted in 96WP format and in three of those non-geometric mefloquine 
concentration range was used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Piperacillin (µg/ml) 
  
1024 512 256 128 64 32 16 8 4 0 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 0 98 75 21 12 9 4 4 6 6 0 
4 98 82 28 15 10 8 8 9 11 5 
6 97 83 32 21 9 8 10 11 9 8 
8 98 98 43 28 16 11 11 13 12 10 
12 98 98 98 98 98 64 29 30 28 25 
16 98 99 98 99 99 98 98 40 49 47 
 APPENDIX 4: Results of the checkerboard assays done in the 384WP format. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Growth inhibition (%) of the first checkerboard assay done in the 384WP 
format. In total three checkerboard assays were conducted in 384WP. Results of the 
third checkerboard assay done in the 384WP format are presented in the results (Figure 
20). 
 
Figure 2. Growth inhibition (%) of the second checkerboard assay done in the 384WP 
format. In total three checkerboard assays were conducted in 384WP. Results of the 
third checkerboard assay done in the 384WP format are presented in the results (Figure 
20). 
  Piperacillin (µg/ml) 
  
0 0 32 32 64 64 1024 1024 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 
0 1 0 3 3 19 15 100 100 
0 1 -2 8 5 23 16 100 100 
6 15 17 100 100 100 100 100 100 
6 14 13 39 33 100 59 100 100 
8 8 25 100 100 100 100 100 100 
8 12 18 100 90 100 100 100 101 
12 100 100 100 100 100 100 100 101 
12 100 100 100 100 100 100 100 100 
  Piperacillin (µg/ml) 
  
0 0 16 16 32 32 64 64 1024 1024 
M
ef
lo
q
u
in
e 
(µ
g
/m
l)
 
0 0 -2 1 5 9 5 17 11 100 100 
0 0 2 3 3 10 7 18 21 100 93 
6 21 25 42 25 100 42 100 100 100 100 
6 19 18 34 28 35 35 100 100 100 100 
8 17 14 98 100 100 100 100 100 100 100 
8 13 14 100 33 100 81 100 100 100 100 
12 100 100 100 100 100 100 100 100 100 101 
12 100 100 100 100 100 100 100 100 100 99 
 APPENDIX 5: Complete results of the plate uniformity assay  
 
 
Figure 1. Heat map presentation of E. coli BAA1161 growth in the first plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min 
0.85 0.70 0.00 0.79 0.76 0.00 0.80 0.69 0.00 0.79 0.73 0.00 0.81 0.68 0.00 0.89 0.68 0.00 0.87 0.74 0.00 0.86 0.84 0.00 
0.84 0.66 0.00 0.87 0.66 0.00 0.74 0.66 0.00 0.75 0.62 0.00 0.72 0.68 0.00 0.81 0.61 0.00 0.73 0.65 0.00 0.78 0.68 0.00 
0.86 0.65 0.00 0.76 0.67 0.00 0.78 0.65 0.00 0.75 0.64 0.00 0.72 0.62 0.00 0.78 0.66 0.00 0.73 0.60 0.00 0.78 0.70 0.00 
0.78 0.66 0.00 0.80 0.64 0.00 0.75 0.65 0.00 0.73 0.72 0.00 0.77 0.63 0.00 0.78 0.65 0.00 0.65 0.68 0.00 0.77 0.71 0.00 
0.87 0.67 0.00 0.78 0.64 0.00 0.72 0.65 0.00 0.73 0.66 0.00 0.72 0.62 0.00 0.74 0.68 0.00 0.77 0.64 0.00 0.79 0.70 0.00 
0.82 0.65 0.00 0.77 0.62 0.00 0.70 0.65 0.00 0.73 0.62 0.00 0.72 0.64 0.00 0.81 0.68 0.00 0.70 0.66 0.00 0.72 0.59 0.00 
0.84 0.63 0.00 0.70 0.62 0.00 0.74 0.65 0.00 0.74 0.64 0.00 0.71 0.62 0.00 0.72 0.65 0.01 0.71 0.61 0.00 0.69 0.65 0.00 
0.75 0.62 0.00 0.71 0.64 0.01 0.72 0.66 0.01 0.72 0.66 0.01 0.72 0.63 0.01 0.74 0.67 0.00 0.69 0.68 0.00 0.77 0.66 0.00 
0.76 0.74 0.00 0.72 0.65 0.00 0.72 0.70 0.01 0.73 0.68 0.00 0.74 0.69 0.00 0.83 0.66 0.00 0.75 0.65 0.00 0.67 0.73 0.00 
0.78 0.68 0.02 0.69 0.64 0.01 0.76 0.64 0.00 0.68 0.68 0.00 0.71 0.69 0.00 0.86 0.69 0.00 0.68 0.64 0.00 0.68 0.65 0.00 
0.79 0.69 0.00 0.70 0.66 0.00 0.73 0.66 0.00 0.79 0.67 0.00 0.79 0.71 0.00 0.72 0.71 0.00 0.66 0.65 0.00 0.73 0.65 0.00 
0.75 0.61 0.00 0.75 0.64 0.00 0.73 0.66 0.00 0.69 0.67 0.00 0.71 0.68 0.00 0.69 0.68 0.01 0.74 0.66 0.03 0.74 0.79 0.00 
0.73 0.62 0.00 0.78 0.69 0.00 0.72 0.64 0.00 0.83 0.70 0.00 0.73 0.68 0.00 0.72 0.70 0.01 0.69 0.69 -0.01 0.72 0.72 0.00 
0.73 0.66 0.00 0.76 0.64 0.00 0.81 0.69 0.00 0.75 0.67 0.00 0.70 0.70 0.00 0.71 0.71 0.00 0.70 0.64 0.00 0.73 0.69 0.00 
0.80 0.68 0.00 0.73 0.74 0.00 0.79 0.75 0.00 0.79 0.68 0.00 0.80 0.67 0.03 0.79 0.69 0.00 0.77 0.68 0.00 0.78 0.68 0.00 
0.86 0.71 0.00 0.80 0.68 0.00 0.82 0.76 0.00 0.78 0.73 0.00 0.87 0.69 0.00 0.82 0.75 0.00 0.82 0.68 0.00 0.84 0.81 0.00 
 Figure 2. Heat map presentation of E. coli BAA1161 growth in the second plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 8 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Figure 3. Heat map presentation of E. coli BAA1161 growth in the Third plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 8 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min 
0.74 -0.01 0.00 0.58 0.42 0.00 0.64 0.38 0.00 0.65 0.42 0.00 0.63 0.39 0.00 0.59 0.00 0.00 0.65 0.41 0.00 0.61 0.42 -0.01 
0.60 0.00 0.00 0.55 0.36 0.00 0.55 0.00 0.00 0.54 0.43 0.00 0.54 0.36 0.00 0.54 0.35 0.00 0.54 0.00 0.00 0.52 0.00 0.00 
0.59 0.36 0.00 0.52 0.36 0.00 0.48 0.38 0.00 0.54 0.00 0.00 0.56 0.39 0.00 0.51 0.55 0.00 0.60 0.36 0.00 0.56 0.11 0.00 
0.59 0.00 0.00 0.53 0.09 0.00 0.54 0.44 0.00 0.53 0.38 0.00 0.50 0.27 0.00 0.52 0.41 0.00 0.51 0.39 0.00 0.46 0.00 0.00 
0.58 0.00 0.00 0.52 0.00 0.00 0.53 0.01 0.00 0.56 0.00 0.00 0.51 0.41 0.00 0.53 0.36 0.00 0.49 0.00 0.00 0.53 0.08 0.00 
0.56 0.39 0.00 0.51 0.00 0.00 0.51 0.00 0.00 0.48 0.00 0.00 0.53 0.41 0.00 0.46 0.35 0.00 0.48 0.37 0.00 0.51 0.39 0.01 
0.63 0.37 0.00 0.52 0.37 0.00 0.56 0.01 0.00 0.54 0.39 0.00 0.54 0.37 0.00 0.54 0.34 0.00 0.51 0.45 0.00 0.52 0.01 0.01 
0.61 0.39 0.00 0.56 0.29 0.00 0.51 0.38 0.00 0.53 0.00 0.00 0.52 0.40 0.00 0.50 0.42 0.00 0.53 0.05 0.01 0.49 0.44 0.01 
0.63 0.00 0.00 0.49 0.41 0.00 0.61 0.00 0.00 0.50 0.44 0.00 0.51 0.00 0.00 0.54 0.40 0.00 0.53 0.07 0.00 0.46 0.01 0.00 
0.58 0.38 0.00 0.53 0.41 0.00 0.53 0.00 0.00 0.51 0.26 0.00 0.50 0.00 0.00 0.49 0.40 0.00 0.50 0.05 0.00 0.52 0.37 0.00 
0.61 0.00 0.00 0.50 0.14 0.00 0.50 0.31 0.00 0.52 0.00 0.00 0.53 0.00 0.00 0.52 0.35 0.00 0.52 0.00 0.00 0.52 0.00 0.00 
0.63 0.42 0.00 0.52 0.38 0.00 0.52 0.41 0.00 0.59 0.00 0.00 0.52 0.40 0.00 0.54 0.44 0.00 0.52 0.00 0.00 0.56 0.15 0.00 
0.67 0.39 0.00 0.52 0.12 0.00 0.52 0.41 0.00 0.55 0.38 0.00 0.53 0.39 0.00 0.52 0.38 0.00 0.55 0.12 0.00 0.58 0.41 0.00 
0.60 0.38 0.00 0.60 0.42 0.00 0.50 0.37 0.00 0.56 0.11 0.00 0.57 0.38 0.00 0.56 0.00 0.00 0.57 0.39 0.01 0.52 0.40 0.00 
0.56 0.41 0.00 0.58 0.38 0.00 0.58 0.00 0.00 0.67 0.33 0.00 0.57 0.00 0.00 0.59 0.46 0.00 0.56 0.39 0.01 0.73 0.18 0.00 
0.72 0.00 0.00 0.68 0.01 0.00 0.62 0.36 0.00 0.65 0.40 0.00 0.63 0.37 0.00 0.59 0.39 -0.01 0.67 0.44 0.00 0.87 0.06 0.00 
Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid 
-0.01 0.76 0.78 0.00 0.40 0.67 0.00 0.80 0.83 0.00 0.29 0.75 0.00 0.77 0.77 0.00 0.68 0.80 0.00 0.74 0.80 0.00 0.82 0.80 
-0.01 0.74 0.00 0.00 0.36 0.75 0.00 0.00 0.75 0.00 0.78 0.73 0.00 0.49 0.74 0.00 0.86 0.63 0.00 0.83 0.00 0.00 0.65 0.00 
-0.01 -0.02 0.47 0.00 0.68 0.65 0.00 0.72 0.00 0.00 0.68 0.00 0.00 0.74 0.46 0.00 0.81 0.00 0.00 0.65 0.73 0.00 0.96 0.09 
0.00 0.81 0.58 0.00 0.65 0.69 0.00 0.65 0.00 0.00 0.74 0.81 0.00 0.70 0.00 0.00 0.73 0.62 0.00 0.65 0.72 0.00 0.60 0.77 
0.00 0.65 0.00 0.00 0.77 0.47 0.00 0.79 0.69 0.00 0.82 0.00 0.00 0.80 0.00 0.00 0.78 0.73 0.00 0.84 0.73 0.00 0.80 0.73 
0.00 0.79 0.70 0.00 0.78 0.67 0.00 0.00 0.71 0.00 0.78 0.00 0.00 0.76 0.77 0.00 0.83 0.66 0.00 0.80 0.72 0.00 0.73 0.76 
0.00 0.65 0.83 0.00 0.81 0.69 0.00 0.76 0.66 0.00 0.77 0.00 0.00 0.77 0.69 0.00 0.80 0.79 0.00 0.68 0.67 0.00 0.77 0.69 
0.00 0.66 0.66 0.00 0.72 0.00 0.00 0.62 0.69 0.00 0.73 0.00 0.00 0.81 0.52 0.00 0.42 0.77 0.00 0.00 0.71 0.00 0.76 0.77 
-0.01 0.66 0.57 0.00 0.81 0.00 0.00 0.74 0.69 0.00 0.79 0.00 0.00 0.53 0.78 0.00 0.83 0.00 0.00 0.76 0.65 0.00 0.80 0.01 
0.00 0.70 0.73 0.00 0.78 0.63 0.00 0.80 0.72 0.00 0.80 0.70 0.00 0.73 0.00 0.00 0.70 0.63 0.00 0.81 0.76 0.00 0.74 0.77 
0.00 0.42 0.53 0.00 0.84 0.71 0.00 0.77 0.71 0.00 0.76 0.67 0.00 0.60 0.72 0.00 0.78 0.51 0.00 0.74 0.66 0.00 0.79 0.00 
0.00 0.81 0.72 0.00 0.80 0.68 0.00 0.75 0.02 0.00 0.71 0.01 0.00 0.62 0.47 0.00 0.75 0.64 0.00 0.76 0.78 0.00 0.71 0.73 
0.00 0.78 0.73 0.00 0.77 0.62 0.00 0.76 0.77 0.00 0.86 0.00 0.00 0.78 0.80 0.00 0.70 0.74 0.00 0.83 0.00 0.00 0.00 0.61 
0.00 0.82 0.74 0.00 0.70 0.00 0.00 0.74 0.00 0.00 0.59 0.70 0.00 0.79 0.00 0.00 0.93 0.00 0.00 0.73 0.66 0.00 0.81 0.65 
0.00 0.92 0.62 0.00 0.76 0.72 0.00 0.78 0.00 0.00 0.81 0.54 0.00 0.82 0.87 0.00 0.81 0.74 0.00 0.85 0.59 0.00 0.77 0.85 
0.00 0.88 0.00 0.00 0.80 0.84 0.00 0.81 0.78 0.00 0.80 0.75 0.00 0.86 0.77 0.00 0.80 0.76 0.00 0.80 0.74 0.00 0.84 0.89 
 Figure 4. Heat map presentation of E. coli BAA1161 growth in the fouth plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Figure 5. Heat map presentation of E. coli BAA1161 growth in the fifth plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max 
0.80 0.00 0.82 0.72 0.00 0.75 0.75 -0.01 0.83 0.71 0.00 0.82 0.68 -0.01 0.83 0.68 0.00 0.99 0.80 -0.01 0.81 0.78 0.00 0.84 
0.72 0.00 0.81 0.00 0.00 0.94 0.00 0.00 0.76 0.00 0.00 0.82 0.68 0.00 0.75 0.70 0.00 0.73 0.61 0.00 0.76 0.70 0.00 0.72 
-0.01 0.00 0.93 0.69 0.00 0.71 0.52 -0.01 0.75 0.71 0.00 0.71 0.00 0.00 0.66 0.62 0.00 0.83 0.66 -0.01 0.79 0.66 0.00 0.81 
0.00 0.00 0.68 0.54 0.00 0.79 0.70 0.00 0.88 0.00 0.00 0.79 0.00 0.00 0.75 0.64 0.00 0.89 0.63 0.00 0.70 0.37 0.00 0.82 
0.64 0.00 0.78 0.71 0.00 0.74 0.75 0.00 0.76 0.70 0.00 0.74 0.64 0.00 0.76 0.67 0.00 0.80 0.75 0.00 0.78 0.48 0.01 0.85 
0.66 0.00 0.73 0.00 0.00 0.71 0.64 0.00 0.73 0.70 0.00 0.78 0.72 0.00 0.78 0.83 0.03 0.79 0.74 0.00 0.73 0.73 0.00 0.81 
0.70 0.00 0.79 0.00 0.00 0.72 0.71 0.00 0.76 0.69 0.00 0.75 0.63 0.00 0.71 0.68 0.01 0.80 0.72 0.01 0.89 0.71 0.00 0.86 
0.70 0.00 0.83 0.65 0.00 0.77 0.66 0.00 0.73 0.69 0.00 0.78 0.61 0.00 0.79 0.73 0.01 0.83 0.43 0.00 0.78 0.73 0.00 0.82 
0.00 0.00 0.73 0.74 0.00 0.86 0.75 0.00 0.71 0.68 0.00 0.86 0.34 0.00 0.78 0.77 0.01 0.79 0.91 0.00 0.83 0.68 0.00 0.81 
0.00 0.00 0.80 0.68 0.00 0.82 0.17 0.00 0.73 0.67 0.00 0.75 0.54 0.04 0.79 0.69 0.00 0.78 0.73 0.00 0.67 0.68 0.00 0.82 
0.70 0.00 0.72 0.74 0.00 0.75 0.72 0.02 0.87 0.72 0.00 0.79 0.01 0.01 0.68 0.67 0.00 0.79 0.50 0.01 0.75 0.75 0.00 0.81 
0.75 0.00 0.82 0.00 0.00 0.66 0.00 0.00 0.78 0.04 0.00 0.75 0.69 0.00 0.81 0.71 0.00 0.76 0.68 0.00 0.86 0.73 0.00 0.81 
0.77 0.00 0.77 0.71 0.00 0.70 0.77 0.00 0.77 0.78 0.00 0.78 0.82 0.02 0.96 0.72 0.00 0.77 0.89 0.00 0.78 0.69 0.00 0.91 
0.73 0.00 0.83 0.64 0.01 0.72 0.72 0.00 0.72 0.71 0.00 0.65 0.48 0.00 0.64 0.54 0.01 0.76 0.00 0.00 0.73 0.71 0.00 0.84 
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 Figure 6. Heat map presentation of E. coli BAA1161 growth in the seventh plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Figure 7. Heat map presentation of E. coli BAA1161 growth in the eighth plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
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 Figure 8a. Heat map presentation of E. coli BAA1161 growth in the ninth plate uniformity assay plate at 24h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Figure 8b. Heat map presentation of E. coli BAA1161 growth in the ninth plate uniformity assay plate at 14h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
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 Figure 8c. Heat map presentation of E. coli BAA1161 growth in the ninth plate uniformity assay plate at 17h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
Figure 8d. Heat map presentation of E. coli BAA1161 growth in the ninth plate uniformity assay plate at 20h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml. 
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0.40 0.13 0.01 0.01 0.25 0.00 0.03 0.01 0.01 0.11 0.01 0.02 0.19 0.01 0.00 0.33 0.13 0.01 0.24 0.00 0.00 0.29 0.35 0.01 
0.08 0.39 0.01 0.00 0.01 0.01 0.22 0.00 0.00 0.01 0.29 0.01 0.03 0.01 0.00 0.01 0.01 0.00 0.17 0.00 0.00 0.00 0.00 0.01 
0.36 0.01 0.01 0.01 0.01 0.00 0.20 0.01 0.00 0.33 0.01 0.02 0.18 0.26 0.01 0.32 0.01 0.00 0.40 0.38 0.00 0.01 0.41 0.01 
Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min 
0.54 0.45 0.01 0.40 0.01 0.01 0.42 0.41 0.02 0.41 0.51 0.01 0.56 0.44 0.01 0.50 0.01 0.01 0.47 0.41 0.01 0.50 0.01 0.01 
0.44 0.44 0.01 0.36 0.41 0.01 0.46 0.01 0.01 0.50 0.01 0.01 0.49 0.01 0.00 0.47 0.48 0.01 0.08 0.44 0.01 0.01 0.01 0.01 
0.39 0.01 0.00 0.47 0.01 0.00 0.37 0.00 0.01 0.44 0.01 0.00 0.47 0.00 0.01 0.50 0.00 0.00 0.52 0.01 0.00 0.01 0.01 0.01 
0.38 0.46 0.01 0.43 0.00 0.00 0.50 0.38 0.00 0.51 0.53 0.00 0.45 0.01 0.01 0.46 0.50 0.00 0.55 0.00 0.00 0.48 0.00 0.01 
0.44 0.01 0.00 0.00 0.53 0.00 0.55 0.00 0.00 0.53 0.00 0.00 0.17 0.01 0.01 0.47 0.00 0.00 0.58 0.01 0.01 0.42 0.40 0.04 
0.46 0.00 0.01 0.33 0.00 0.00 0.44 0.00 0.00 0.47 0.46 0.00 0.33 0.43 0.01 0.02 0.54 0.02 0.06 0.02 0.06 0.09 0.01 0.04 
0.40 0.43 0.00 0.54 0.26 0.00 0.42 0.56 0.00 0.54 0.00 0.00 0.51 0.00 0.01 0.41 0.54 0.05 0.44 0.53 0.01 0.52 0.01 0.01 
0.46 0.43 0.01 0.01 0.53 0.00 0.52 0.53 0.00 0.42 0.00 0.00 0.36 0.47 0.00 0.55 0.53 0.04 0.04 0.35 0.00 0.45 0.02 0.01 
0.45 0.41 0.00 0.42 0.51 0.01 0.39 0.27 0.01 0.05 0.46 0.02 0.56 0.53 0.01 0.47 0.53 0.01 0.48 0.02 0.01 0.52 0.05 0.01 
0.45 0.00 0.01 0.17 0.01 0.00 0.51 0.00 0.01 0.51 0.01 0.03 0.59 0.57 0.06 0.59 0.60 0.04 0.54 0.05 0.04 0.15 0.08 0.01 
0.47 0.01 0.01 0.50 0.00 0.01 0.52 0.53 0.00 0.53 0.35 0.01 0.43 0.02 0.03 0.34 0.04 0.03 0.46 0.46 0.05 0.48 0.47 0.00 
0.42 0.50 0.01 0.16 0.00 0.01 0.02 0.46 0.00 0.56 0.40 0.01 0.55 0.47 0.03 0.55 0.53 0.03 0.42 0.42 0.00 0.03 0.01 0.00 
0.59 0.01 0.00 0.49 0.00 0.01 0.50 0.01 0.00 0.50 0.01 0.01 0.49 0.01 0.00 0.48 0.00 0.00 0.43 0.02 0.00 0.44 0.42 0.00 
0.50 0.43 0.01 0.26 0.47 0.00 0.41 0.01 0.02 0.44 0.01 0.02 0.49 0.02 0.01 0.49 0.45 0.01 0.47 0.01 0.00 0.47 0.48 0.01 
0.42 0.50 0.01 0.01 0.01 0.01 0.47 0.01 0.01 0.40 0.49 0.01 0.22 0.12 0.02 0.01 0.01 0.03 0.46 0.02 0.00 0.01 0.00 0.01 
0.58 0.01 0.01 0.17 0.01 0.00 0.46 0.01 0.00 0.49 0.01 0.02 0.45 0.43 0.15 0.48 0.01 0.09 0.49 0.58 0.00 0.42 0.48 0.01 
 Figure 8e. Heat map presentation of E. coli BAA1161 growth in the ninth plate uniformity assay plate at 28h. The treatment of column’s 
wells is presented above it in the figure. The treatments were: max: 256 μg/ml piperacillin, mid: 256 μg/ml piperacillin + 6 μg/ml 
mefloquine, min: 256 μg/ml piperacillin + 16 μg/ml mefloquine. Initial bacterial concentration of all the wells was 5x105 cfu/ml.
Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min Max Mid Min 
0.99 0.89 0.01 0.88 0.01 0.01 1.00 0.88 0.01 0.89 0.94 0.01 1.03 0.89 0.01 1.00 0.01 0.01 0.98 0.87 0.01 1.03 0.67 0.00 
0.95 0.87 0.01 0.84 0.83 0.01 0.95 0.01 0.01 0.99 0.01 0.01 0.98 0.41 0.01 0.96 0.91 0.01 0.74 0.90 0.01 0.01 0.01 0.01 
0.86 0.62 0.00 0.96 0.01 0.00 0.83 0.44 0.01 0.93 0.01 0.00 0.95 0.00 0.01 0.98 0.00 0.00 1.00 0.54 0.02 0.42 0.01 0.01 
0.84 0.88 0.01 0.93 0.01 0.01 0.97 0.78 0.00 0.98 0.93 0.02 0.93 0.01 0.01 0.93 0.91 0.01 1.00 0.00 0.02 0.98 0.01 0.01 
0.94 0.01 0.01 0.00 0.95 0.00 1.00 0.02 0.00 0.99 0.04 0.05 0.92 0.29 0.01 0.96 0.00 0.00 1.05 0.42 0.01 0.92 0.85 0.03 
0.95 0.01 0.01 0.99 0.01 0.00 0.90 0.01 0.01 0.93 0.86 0.03 0.81 0.87 0.01 0.02 0.93 0.02 0.62 0.02 0.02 0.08 0.01 0.03 
0.89 0.83 0.00 0.99 0.72 0.00 0.87 0.95 0.02 0.99 0.00 0.00 0.97 0.52 0.02 0.90 0.94 0.05 0.91 0.94 0.01 1.00 0.02 0.01 
0.94 0.83 0.01 0.55 0.93 0.01 0.96 0.93 0.01 0.89 0.01 0.00 0.82 0.89 0.01 1.00 0.93 0.03 0.04 0.77 0.01 0.95 0.03 0.02 
0.97 0.78 0.01 0.87 0.92 0.03 0.95 0.71 0.01 0.03 0.85 0.02 1.00 0.92 0.01 0.93 0.93 0.01 1.02 0.02 0.01 1.01 0.91 0.04 
0.95 0.01 0.01 0.75 0.01 0.02 0.97 0.42 0.01 0.97 0.01 0.02 1.01 0.95 0.03 1.05 0.97 0.02 0.97 0.03 0.06 0.77 0.05 0.03 
0.97 0.01 0.01 0.97 0.00 0.01 0.98 0.92 0.03 1.01 0.95 0.01 0.90 0.01 0.01 0.80 0.02 0.02 0.94 0.90 0.16 1.01 0.98 0.04 
0.93 0.92 0.01 0.76 0.00 0.01 0.64 0.91 0.05 1.02 0.78 0.01 1.00 0.91 0.01 1.00 0.95 0.01 0.89 0.83 0.02 0.71 0.62 0.01 
1.05 0.01 0.00 0.99 0.07 0.01 0.98 0.01 0.00 1.00 0.01 0.01 0.98 0.01 0.01 0.98 0.15 0.01 0.92 0.02 0.01 0.99 0.89 0.02 
0.97 0.85 0.01 1.00 0.91 0.01 0.89 0.01 0.01 0.94 0.01 0.01 0.98 0.02 0.01 1.02 0.88 0.02 0.98 0.48 0.01 1.00 0.98 0.05 
0.95 0.92 0.01 0.55 0.01 0.01 0.99 0.01 0.01 0.87 0.93 0.01 0.80 0.82 0.01 0.01 0.01 0.05 1.01 0.05 0.03 0.60 0.03 0.02 
0.94 0.01 0.02 0.83 0.01 0.01 1.02 0.02 0.01 1.02 0.02 0.02 0.99 0.91 0.02 1.01 0.01 0.08 1.03 1.02 0.02 0.93 0.93 0.02 
 APPENDIX 6: Complete results of the DMSO compatibility assays  
 
 
Figure 1. Heat map presentation of the E. coli BAA1161 growth inhibition in the first DMSO compatibility assay. Bacterial growth 
inhibition of DMSO was studied with seven DMSO concentrations in presence and in absence of 256 μg/ml PIP. Values presented in the 
table are growth inhibition percentages measured at 24h time point. 
 
 
Figure 2. Heat map presentation of the E. coli BAA1161 growth inhibition in the second DMSO compatibility assay. Bacterial growth 
inhibition of DMSO was studied with seven DMSO concentrations in presence and in absence of 256 μg/ml PIP. Values presented in the 
table are growth inhibition percentages measured at 24h time point. 
 
   DMSO concentration (%) 
P
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ill
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co
n
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at
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(μ
g/
m
l)
 
 
0 0 0.5 0.5 1 1 2 2 3 3 4 4 5 5 
0 8 -3 -11 -8 -12 -12 -10 -5 -8 -4 0 4 19 38 
0 3 -9 -15 -16 -13 -14 -10 -10 -5 -9 -1 -2 11 21 
256 21 97 22 37 34 90 35 97 46 53 47 56 58 68 
256 39 98 98 18 25 47 40 98 46 39 53 49 59 75 
   DMSO concentration (%) 
P
ip
er
ac
ill
in
 
co
n
ce
n
tr
at
io
n
 
(μ
g/
m
l)
 
 
0 0 0.5 0.5 1 1 2 2 3 3 4 4 5 5 
0 8 0 -9 -9 -7 -10 -8 -4 -3 -3 6 7 27 39 
0 1 -9 -16 -17 -15 -15 -10 -11 -7 -8 2 1 20 30 
256 34 19 26 33 94 27 37 34 41 42 50 48 56 63 
256 48 26 25 26 30 25 36 37 34 41 47 51 62 69 
 APPENDIX 7: Complete results of the test screen  
 
 
Figure 1. Heat map presentation of the growth inhibition values (%) of the natural compounds in the first plate of the test EPI screen at 24h 
time point. Growth inhibition effect of 256 μg/ml piperacillin, which in combination with the natural compounds were screened, is 
subtracted from the presented growth inhibition values. Replicate wells with the same natural compound are separated by the thin lines. In 
the figure, replicate wells of the compounds which were considered hits and were tested in the follow-up dose-response assays are 
surrounded by thick lines. From left to right, wells inside the thick lines contained epigallocatechin gallate, hamamelitannin and isopropyl 
gallate. 
 
 
 
1.1 47.4 49.0 -6.0 9.3 14.4 -2.3 5.5 -4.4 9.5 17.8 18.5 13.2 9.4 9.3 8.9 0.2 -0.4 
25.0 1.7 3.9 33.5 -9.1 9.7 6.7 2.2 -1.9 20.9 15.9 15.1 42.0 10.5 -4.7 10.1 92.8 2.4 
4.5 13.8 -9.2 5.0 23.0 3.8 -15.5 4.8 5.9 5.3 -1.0 -4.2 -6.5 -6.6 2.0 10.0 39.4 100.1 
-5.1 -3.8 0.8 4.2 4.9 -9.6 3.6 -16.4 1.2 -6.0 5.4 10.1 -6.6 -4.6 0.5 -1.6 -1.6 68.3 
-5.7 -4.7 -1.7 -6.2 -9.6 22.6 3.2 8.3 0.0 -4.7 35.1 33.3 0.2 -0.9 -1.7 -4.4 14.0 2.5 
-3.9 4.0 2.5 18.7 21.8 15.5 10.1 -6.4 11.7 8.5 30.9 32.8 4.0 1.3 -2.5 13.2 -3.7 20.5 
4.9 4.4 9.4 -1.0 3.1 26.6 14.3 0.1 -2.3 -2.2 3.3 -4.0 -11.8 0.5 3.8 -13.8 -24.6 -0.8 
5.2 10.6 4.4 -5.2 -1.0 10.5 -9.9 -2.6 -2.0 -4.9 -9.2 -5.8 -21.6 8.9 1.0 10.9 -2.2 6.8 
7.9 -0.1 10.6 3.2 -6.0 10.1 -7.1 3.1 -3.4 19.2 -2.9 8.3 -1.8 -5.1 -5.3 -1.3 -5.1 -7.1 
18.0 -0.2 19.3 1.1 -0.9 1.0 -11.1 -3.8 -0.2 2.0 3.5 5.9 -0.4 -4.5 -2.5 -1.6 -0.5 -5.3 
8.2 -9.4 -2.8 36.8 -3.1 -5.6 0.8 -10.3 99.9 6.1 0.9 8.2 28.5 36.6 -10.3 -1.6 0.3 -5.1 
99.9 -21.6 -0.2 5.6 7.7 75.7 -3.7 3.1 -3.5 -9.2 1.4 -10.3 32.2 20.9 -4.3 -7.7 2.3 0.5 
3.9 23.8 11.6 -0.2 -3.0 9.5 8.6 8.5 3.2 2.7 14.7 12.1 25.6 -4.7 3.7 0.1 -1.1 27.7 
-1.8 21.1 -6.3 1.7 -0.3 -0.9 1.8 -3.7 1.5 -1.2 11.6 28.3 17.1 -4.7 -1.1 -1.1 -15.1 3.6 
  
 
 
Figure 2. Heat map presentation of the growth inhibition values (%) of the natural compounds in the second plate of the test EPI screen at 
24h time point. Growth inhibition effect of 256 μg/ml piperacillin, which in combination with the natural compounds were screened, is 
subtracted from the presented growth inhibition values. Replicate wells with the same natural compound are separated by the thin lines. In 
the figure, replicate wells of the octyl gallate, which was considered as a hit and was included in the follow-up dose-response assays, are 
surrounded by thick lines. 
 
 
7.0 -1.3 2.3 0.5 -1.4 -1.4 -6.8 -0.1 -0.8 4.9 9.8 -0.9 7.2 6.0 10.4 2.4 -2.3 5.5 
-1.1 -7.7 12.6 13.9 6.3 -3.6 -0.3 5.5 100.1 5.5 20.9 -2.3 7.8 11.0 4.9 17.4 24.5 20.2 
10.4 10.1 -7.8 -16.5 4.3 3.7 -1.7 20.2 7.6 30.0 13.7 3.8 12.3 -18.2 -3.8 37.3 7.7 17.9 
7.5 8.2 4.1 2.0 -0.8 -0.6 -5.1 19.0 4.0 -2.9 8.7 -4.7 -0.8 3.7 -20.6 -3.4 -4.0 3.0 
4.5 -3.4 11.4 20.3 -15.0 1.0 -0.5 -11.9 2.7 -4.0 -7.9 0.6 1.9 8.0 -5.0 -18.0 -4.4 0.2 
-14.7 3.1 14.8 11.4 0.2 -17.8 -15.6 -2.3 -6.5 0.0 3.8 12.2 -2.1 -12.6 5.0 -5.2 -2.4 2.8 
2.5 16.2 37.7 48.3 -2.5 3.0 -1.3 -4.4 -5.2 -1.2 2.3 9.7 -9.1 -2.8 -12.9 -1.4 -10.3 1.8 
-15.1 37.1 46.3 47.1 1.6 -0.7 -4.7 -7.9 0.7 -7.1 5.7 -1.6 -11.4 2.2 10.0 6.6 -2.6 -0.3 
1.8 4.9 -2.7 -16.1 38.2 -7.6 -1.2 -12.4 3.9 11.3 5.6 1.8 -1.6 -4.7 -10.3 30.9 -1.0 -9.8 
9.3 -3.7 6.9 -3.1 -3.1 -3.0 3.0 -10.5 -5.7 4.8 -0.1 7.4 -0.5 0.0 1.1 -7.0 1.6 0.9 
-4.6 5.5 -4.4 0.4 1.7 0.7 -3.5 -4.7 -5.1 -1.4 11.9 -2.2 7.6 -4.7 -7.0 -3.6 -8.2 -6.9 
-9.1 -6.5 7.7 6.6 18.0 -0.4 -0.9 1.4 0.6 10.8 5.9 -4.7 18.3 -4.9 -5.9 3.1 -1.0 -8.5 
3.3 16.4 8.1 14.7 6.6 4.9 5.4 10.2 4.1 -1.9 99.9 -1.3 46.8 3.9 1.1 17.8 -1.2 2.0 
-2.9 17.6 6.2 -0.1 -5.4 -2.0 7.6 -3.3 -2.9 -7.2 -1.4 3.1 1.9 -1.5 -0.7 8.6 100.1 -8.4 
 APPENDIX 8: Results of the second dose-response assay  
 
Table 1. Results of the second dose response assay. Growth inhibition effect of the four 
hit natural compounds (NC) was tested at six concentrations in combination with and 
without 256 μg/ml piperacillin (PIP). Growth inhibition values (%) of all wells included 
in the assay are presented in the figure. Inconsistent and random over 97% growth 
inhibition values were occurring in the wells with 256 μg/ml PIP. 
*EGCG=Epigallocatechin gallate, HT=Hamamelitannin, IG=Isopropyl gallate and 
OG=Octyl gallate 
Natural 
compound* 
PIP 
concentration 
(μg/ml) 
Natural compound concentration (μM) 
  100 75 50 25 12.5 0 
EGCG 
0 
12.3 13.9 10.7 7.5 1.8 -3.9 
15.7 16.4 17.0 12.6 4.1 0.7 
14.6 15.9 12.4 8.3 2.1 -3.4 
256 
56.5 52.1 48.4 43.6 42.6 100.2 
53.8 50.4 54.8 61.0 36.2 48.8 
50.4 51.3 55.9 56.7 40.9 46.5 
HT 
0 
5.3 12.8 13.7 4.2 6.0 2.3 
9.9 11.9 11.1 6.5 6.3 2.1 
8.8 12.9 11.7 7.3 5.6 -0.6 
256 
53.0 97.4 45.0 40.2 45.7 53.4 
52.0 59.7 48.8 52.3 41.9 25.6 
59.8 61.0 99.1 48.1 42.8 29.6 
IG 
0 
10.1 9.8 12.6 5.9 6.9 2.1 
9.2 9.7 11.1 6.2 5.3 4.3 
10.6 9.8 9.9 7.8 4.9 -0.5 
256 
66.9 53.7 63.0 100.0 46.8 100.0 
55.9 54.0 61.7 99.9 53.2 43.9 
68.9 67.5 50.8 99.9 45.1 40.0 
OG 
0 
17.8 17.9 11.7 7.0 2.0 0.1 
12.8 14.0 11.8 1.5 0.1 -1.5 
19.8 14.6 14.8 5.5 3.2 -1.7 
256 
99.8 99.9 60.0 49.0 43.2 62.3 
99.8 99.9 55.5 45.0 99.9 33.5 
99.8 99.7 55.3 51.4 44.7 100.0 
